BLOOD ADV 2021 10.1182/bloodadvances.2020004074

Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma

Tam¹, CS; Opat, S; Simpson, D; Cull, G; Munoz, J; Phillips, TJ; Kim, WS; Rule, S; Atwal, SK; Wei, R; Novotny, W; Huang, J; Wang, M; Trotman, J

LANCET HAEMATOL 2021

Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial

Straus¹, DJ; Dlugosz-Danecka, M; Connors, JM; Alekseev, S; Illes, A; Picardi, M; Lech-Maranda, E; Feldman, T; Smolewski, P; Savage, KJ; Bartlett, NL; Walewski, J; Ramchandren, R; Zinzani, PL; Hutchings, M; Munoz, J; Lee, HJ; Kim, WS; Advani, R; Ansell, SM; Younes, A; Gallamini, A; Liu, R; Little, M; Fenton, K; Fanale, M; Radford, J

ANTIVIR RES 2021 10.1016/j.antiviral.2021.105063

Sildenafil prevents HDACi-induced Epstein-Barr virus reactivation through the PKG pathway in NK/T cell lymphoma; potential implications for HDACi-mediated fatal complications

Kim¹, JH; Kim, WS; Park, C

CANCER MANAG RES 2021 10.2147/CMAR.S309092

Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma

Lee¹, YP; Hong, JY; Yoon, SE; Cho, J; Shim, JH; Bang, Y; Kim, WS; Kim, SJ

KOREAN J INTERN MED 2021 10.3904/kjim.2019.367

Real-world data on the survival outcome of patients with newly diagnosed Waldenstrom macroglobulinemia

Cho¹, JH; Shim, JH; Yoon, SE; Kim, HJ; Kim, SH; Ko, YH; Lee, ST; Kim, K; Kim, WS; Kim, SJ

SCI REP-UK 2021 10.1038/s41598-021-89754-8

EGR1 as a potential marker of prognosis in extranodal NK/T-cell lymphoma

Lee¹, JY; Kim, JH; Bang, H; Cho, J; Ko, YH; Kim, SJ; Kim, WS

EXP HEMATOL ONCOL 2021 10.1186/s40164-021-00224-3

Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas

Yoon¹, SE; Cho, J; Kim, YJ; Ko, YH; Park, WY; Kim, SJ; Kim, WS

SCI REP-UK 2021 10.1038/s41598-021-88815-2

Role in staging and prognostic value of pretherapeutic F-18 FDG PET/CT in patients with gastric MALT lymphoma without high-grade transformation

Park¹, YJ; Hyun, SH; Moon, SH; Lee, KH; Min, BH; Lee, JH; Kim, WS; Kim, SJ; Choi, JY

ANN ONCOL 2021 10.1016/j.annonc.2020.12.009

Combination treatment of copanlisib and gemcitabine in relapsed refractory PTCL (COSMOS): an open-label phase I/II trial

Yhim¹, HY; Kim, T; Kim, SJ; Shin, HJ; Koh, Y; Kim, JS; Park, J; Park, GS; Kim, WS; Moon, JH; Yang, DH

SCI REP-UK 2021 10.1038/s41598-021-85332-0

Metabolic activity of extranodal NK/T cell lymphoma on F-18-FDG PET/CT according to immune subtyping

Lim¹, CH; Yoon, SE; Kim, SJ; Cho, J; Ko, YH; Lee, KH; Kim, WS

FRONT ONCOL 2021 10.3389/fonc.2021.628807

Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Lee¹, B; Lee, H; Cho, J; Yoon, SE; Kim, SJ; Park, WY; Kim, WS; Ko, YH

CANCER COMMUN 2021 10.1002/cac2.12150

Real-world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis

Yi¹, JH; Kim, SJ; Yoon, DH; Suh, C; Chang, MH; Yang, DH; Jo, JC; Hyun, SY; Eom, HS; Lee, JO; Kwon, JH; Han, SH; Lee, SS; Kwak, JY; Kim, SH; Kim, DS; Lee, JH; Oh, SY; Ryoo, HM; Kim, HJ; Kim, WS

J CANCER 2021 10.7150/jca.54434

Impact of transformation on the survival of patients diagnosed with follicular lymphoma that progressed within 24 months

Yoon¹, SE; Cho, J; Kim, WS; Kim, SJ

J HEMATOL ONCOL 2021 10.1186/s13045-020-01020-y

Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study

Huang¹, HQ; Zhu, J; Yao, M; Kim, TM; Yoon, DH; Cho, SG; Eom, HS; Lim, ST; Yeh, SP; Song, YQ; Kwong, YL; Kim, JS; Jin, J; Shi, YK; Kim, H; Qing, M; Zhou, TY; Gao, G; Dong, ZQ; Qi, M; Kim, WS

JPN J CLIN ONCOL 2021 10.1093/jjco/hyaa177

Phase I studies of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: a pooled analysis of two phase I studies conducted in Japan and Korea

Ogura¹, M; Kim, WS; Uchida, T; Uike, N; Suehiro, Y; Ishizawa, K; Nagai, H; Nagahama, F; Sonehara, Y; Tobinai, K

BMC CANCER 2021 10.1186/s12885-021-07806-8

The mutation of BCOR is highly recurrent and oncogenic in mature T-cell lymphoma

Kang¹, JH; Lee, SH; Lee, J; Choi, M; Cho, J; Kim, SJ; Kim, WS; Ko, YH; Yoo, HY

BONE MARROW TRANSPL 2020 10.1038/s41409-020-01160-2

Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphoma

Song¹, GY; Yoon, DH; Suh, C; Moon, JH; Baek, DW; Kim, JS; Lee, GW; Yi, JH; Park, Y; Jung, KS; Kim, SJ; Yang, DH; Kim, WS

BLOOD 2020

Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma an open-label phase 2 study

Kim¹, SJ; Lim, JQ; Laurensia, Y; Cho, J; Yoon, SE; Lee, JY; Ryu, KJ; Ko, YH; Koh, Y; Cho, D; Lim, ST; Enemark, MB; D'amore, F; Bjerre, M; Ong, CK; Kim, WS

CANCERS 2020 10.3390/cancers12123548

Serum-Derived Exosomal MicroRNA Profiles Can Predict Poor Survival Outcomes in Patients with Extranodal Natural Killer/T-Cell Lymphoma

Ryu¹, KJ; Lee, JY; Choi, ME; Yoon, SE; Cho, J; Ko, YH; Shim, JH; Kim, WS; Park, C; Kim, SJ

APPL IMMUNOHISTOCHEM MOL MORPHOL 2020 10.1097/PAI.0000000000000843

Comparison of the Lymph2Cx Assay and Hans Algorithm in Determining the Cell-of-Origin of Diffuse Large B-Cell Lymphomas, Not Otherwise Specified

Cho¹, I; Yoon, N; Hyeon, J; Sim, J; Yoo, HY; Kim, SJ; Kim, WS; Ko, YH

J COSMET DERMATOL 2020 10.1111/jocd.13383

Auricular keloid management in Asian skin Clinical outcome of intralesional excision and postoperative triamcinolone acetonide intralesional injection

Choi¹, YJ; Lee, YH; Lee, HJ; Lee, GY; Kim, WS

BLOOD 2020 10.1182/blood.2020005026

Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma

Kim¹, H; Jeong, H; Yamaguchi, M; Sohn, I; Yoon, SE; Byeon, S; Hur, JY; Koh, Y; Yoon, SS; Kim, EJ; Oguchi, M; Miyazaki, K; Taguchi, S; Yoon, DH; Cho, J; Ko, YH; Kim, SJ; Suzuki, R; Kim, WS

BLOOD ADV 2020 10.1182/bloodadvances.2020002814

A risk model for relapsed/refractory aggressive NHL integrating clinical risk factors and pretransplant Deauville score

Yhim¹, HY; Eshet, Y; Metser, U; Lim, CH; Lajkosz, K; Isaev, K; Cooper, M; Prica, A; Kukreti, V; Bhella, S; Lang, N; Lee, KH; Xu, W; Hodgson, D; Tsang, R; Yoon, SE; Kim, SJ; Kim, WS; Crump, M; Kuruvilla, J; Kridel, R

SCI REP-UK 2020 10.1038/s41598-020-74796-1

Hair growth promotion by necrostatin-1s

Zheng¹, M; Choi, N; Jang, YJ; Kwak, E; Kim, Y; Kim, WS; Oh, SH; Sung, JH

CANCERS 2020 10.3390/cancers12082192

First-Line Treatment for Primary Breast Diffuse Large B-Cell Lymphoma Using Immunochemotherapy and Central Nervous System Prophylaxis A Multicenter Phase 2 Trial

Yhim¹, HY; Yoon, DH; Kim, SJ; Yang, DH; Eom, HS; Ha Kim, K; Park, Y; Kim, JS; Kim, HJ; Suh, C; Kim, WS; Kwak, JY

PATIENT EDUC COUNS 2020 10.1016/j.pec.2020.03.007

Association between sexuality knowledge and sexual dysfunction in hematopoietic stem cell transplantation patients and their partners

Kim¹, IR; Jang, SY; Shin, HS; Choi, HJ; Jung, CW; Yoon, SS; Kim, JS; Kim, SJ; Kim, K; Kim, WS; Lee, CH; Kang, D; Cho, J

LEUKEMIA 2020 10.1038/s41375-020-1000-0

Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma

Lim¹, JQ; Huang, DC; Tang, T; Tan, D; Laurensia, Y; Peng, RJ; Wong, EKY; Cheah, DMZ; Chia, BKH; Iqbal, J; Grigoropoulos, NF; Nairismagi, ML; Ng, CCY; Rajasegaran, V; Hong, HM; Kim, SJ; Cho, J; Tse, E; Mow, B; Cai, QC; Poon, L; Cai, QQ; Tan, J; Chan, JY; Lim, JX; Goh, YT; Phipps, C; Rotzschke, O; Cheng, CL; Ha, JCH; Khoo, LP; Loh, YSM; Au-Yeung, R; Chan, TSY; Kwong, YL; Hwang, W; Kim, WS; Bei, JX; Lin, TY; Ong, CK; Lim, ST

KOREAN JOURNAL OF INTERNAL MEDICINE 2020 10.3904/kjim.2018.396

Asian variant of intravascular large B-cell lymphoma a comparison of clinical features based on involvement of the central nervous system

Yoon¹, SE; Kim, WS; Kim, SJ

CELL PROLIFERAT 2020 10.1111/cpr.12881

Epiregulin promotes hair growth via EGFR-medicated epidermal and ErbB4-mediated dermal stimulation

Choi¹, N; Kim, WS; Oh, SH; Sung, JH

LASER MED SCI 2020 10.1007/s10103-019-02906-1

Split-face comparison of the picosecond 1064-nm Nd:YAG laser using a microlens array and the quasi-long-pulsed 1064-nm Nd:YAG laser for treatment of photoaging facial wrinkles and pores in Asians

Yim¹, S; Lee, YH; Choi, YJ; Kim, WS

ANN HEMATOL 2020 10.1007/s00277-020-04005-6

A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis

Yoon¹, SE; Kim, SJ; Yoon, KH; Koh, Y; Mun, YC; Do, YR; Choi, YS; Yang, DH; Kim, MK; Lee, GW; Suh, C; Ko, YH; Kim, WS

ANN HEMATOL 2020 10.1007/s00277-020-04008-3

Plasma cell-free DNA is a prognostic biomarker for survival in patients with aggressive non-Hodgkin lymphomas

Hur¹, JY; Kim, YJ; Yoon, SE; Son, DS; Park, WY; Kim, SJ; Park, D; Kim, WS

Lancet Haematol 2020

Survival outcomes for extranodal natural-killer T-cell lymphoma

Fox¹, CP; Civallero, M; Federico, M; Kim, WS

ANN HEMATOL 2020 10.1007/s00277-020-04083-6

A comprehensive analysis of adult patients with secondary hemophagocytic lymphohistiocytosis: a prospective cohort study

Yoon¹, SE; Eun, Y; Huh, K; Chung, CR; Yoo, IY; Cho, J; Cho, D; Ko, YH; Park, S; Kim, WS; Kim, SJ

CYTOKINE 2020 10.1016/j.cyto.2020.155048

Pre-treatment serum IL-10 predicts the risk of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma

Yi¹, JH; Yoon, SE; Ryu, KJ; Ko, YH; Kim, WS; Kim, SJ

Lancet Haematol 2020 10.1016/S2352-3026(19)30283-2

Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project

Fox¹, CP; Civallero, M; Ko, YH; Manni, M; Skrypets, T; Pileri, S; Kim, SJ; Cabrera, ME; Shustov, AR; Chiattone, CS; Horwitz, SM; Dlouhy, I; Spina, M; Hitz, F; Montoto, S; Nagler, A; Martinez, V; De Souza, CA; Fernandez-Alvarez, R; Ballova, V; Gabus, R; Inghirami, G; Federico, M; Kim, WS

MODERN PATHOL 2020 10.1038/s41379-019-0392-8

Immune subtyping of extranodal NK/T-cell lymphoma: a new biomarker and an immune shift during disease progression

Cho¹, J; Kim, SJ; Park, WY; Kim, J; Woo, J; Kim, G; Yoon, SE; Ko, YH; Kim, WS

CANCER RES TREAT 2020 10.4143/crt.2019.198

Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial

Kim¹, SJ; Yoon, DH; Kim, JS; Kang, HJ; Lee, HW; Eom, HS; Hong, JY; Cho, J; Ko, YH; Huh, J; Yang, WI; Park, WS; Lee, SS; Suh, C; Kim, WS

J HEMATOL ONCOL 2020 10.1186/s13045-020-00855-9

Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group

Yoon¹, DH; Cao, JN; Chen, TY; Izutsu, K; Kim, SJ; Kwong, YL; Lin, TY; Thye, LS; Xu, B; Yang, DH; Kim, WS

BLOOD 2020 10.1182/blood.2019003127

Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study

Straus¹, DJ; Dlugosz-Danecka, M; Alekseev, S; Illes, A; Picardi, M; Lech-Maranda, E; Feldman, T; Smolewski, P; Savage, KJ; Bartlett, NL; Walewski, J; Ramchandren, R; Zinzani, PL; Hutchings, M; Connors, JM; Radford, J; Munoz, J; Kim, WS; Advani, R; Ansell, SM; Younes, A; Miao, H; Liu, R; Fenton, K; Forero-Torres, A; Gallamini, A

BLOOD ADV 2020 10.1182/bloodadvances.2019001114

Progression of AITL-like tumors in mice is driven by Tfh signature proteins and T-B cross talk

Witalis¹, M; Chang, J; Zhong, MC; Bouklouch, Y; Panneton, V; Li, JN; Buch, T; Kim, SJ; Kim, WS; Ko, YH; Veillette, A; Suh, WK

BMC CANCER 2020 10.1186/s12885-020-6612-2

Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma

Cho¹, I; Lee, H; Yoon, SE; Ryu, KJ; Ko, YH; Kim, WS; Kim, SJ

PSYCHO-ONCOL 2020 10.1002/pon.5265

Impact of fear of cancer recurrence on survival among lymphoma patients

Kim¹, SJ; Kang, D; Kim, IR; Yoon, SE; Kim, WS; Butow, PN; Guallar, E; Cho, J

LEUKEMIA 2020 10.1038/s41375-020-0740-1

A proposal for a new staging system for extranodal natural killer T-cell lymphoma: a multicenter study from China and Asia Lymphoma Study Group

Hong¹, HM; Li, YX; Lim, ST; Liang, CY; Huang, H; Yi, PY; Wu, T; Du, X; Zhang, MZ; Wang, JH; Zhu, J; Liu, T; Meng, FY; Wu, G; Guo, Y; Zhu, Y; Zhao, WL; Jin, J; Li, J; Deng, YM; Gu, KS; Wu, XY; Ke, XY; Xie, DR; Lin, DR; Peng, ZG; Wu, JX; Liu, Q; Kim, W; Lin, TY

ANN HEMATOL 2020 10.1007/s00277-019-03891-9

A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin's lymphoma

Won¹, YW; Lee, H; Eom, HS; Kim, JS; Suh, C; Yoon, DH; Hong, JY; Kang, HJ; Lee, JH; Kim, WS; Kim, SJ; Lee, WS; Chang, MH; Do, YR; Yi, JH; Kim, I; Won, JH; Kim, K; Oh, SY; Jo, JC

ANN DERMATOL 2020 10.5021/ad.2020.32.1.8

A Split-Face, Single-Blinded, Randomized Controlled Comparison of 532 nm Picosecond Neodymium-Doped Yttrium Aluminum Garnet Laser versus 532 nm Q-Switched Neodymium-Doped Yttrium Aluminum Garnet Laser in the Treatment of Solar Lentigines

Kim¹, JY; Yang, J; Huh, G; Choi, YJ; Kim, WS

LANCET ONCOL 2020 10.1016/S1470-2045(19)30799-5

Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations

Lin¹, GW; Xu, CG; Chen, KX; Huang, HQ; Chen, JP; Song, B; Chan, JKC; Li, WY; Liu, WP; Shih, LY; Chuang, WY; Kim, WS; Tan, W; Peng, RJ; Laurensia, Y; Cheah, DMZ; Huang, DC; Cheng, CL; Su, YJ; Tan, SY; Ng, SB; Tang, TPL; Han, K; Wang, VYF; Jia, WH; Pei, Z; Li, YJ; Gao, S; Shi, YY; Hu, ZB; Zhang, FR; Zhang, B; Zeng, YX; Shen, HB; He, L; Ong, CK; Lim, ST; Chanock, S; Kwong, YL; Lin, DX; Rothman, N; Khor, CC; Lan, Q; Bei, JX

INT J MOL SCI 2020 10.3390/ijms21010122

HB-EGF Improves the Hair Regenerative Potential of Adipose-Derived Stem Cells via ROS Generation and Hck Phosphorylation

Choi¹, N; Kim, WS; Oh, SH; Sung, JH

KOREAN JOURNAL OF INTERNAL MEDICINE 2020 10.3904/kjim.2018.196

Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance

Kim¹, HK; Kang, W; Sinn, DH; Lee, JH; Kim, WS; Kim, SJ

J CLIN ONCOL 2020 10.1200/JCO.19.00172

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Sehn¹, LH; Herrera, AF; Flowers, CR; Kamdar, MK; McMillan, A; Hertzberg, M; Assouline, S; Kim, TM; Kim, WS; Ozcan, M; Hirata, J; Penuel, E; Paulson, JN; Cheng, J; Ku, G; Matasar, MJ

ANN HEMATOL 2019 10.1007/s00277-019-03791-y

Multicenter retrospective analysis of the clinicopathologic features of monomorphic epitheliotropic intestinal T-cell lymphoma

Yi¹, JH; Lee, GW; Do, YR; Jung, HR; Hong, JY; Yoon, DH; Suh, C; Choi, YS; Yi, SY; Sohn, BS; Kim, BS; Oh, SY; Park, J; Jo, JC; Lee, SS; Oh, YH; Kim, SJ; Kim, WS

AM J HEMATOL 2019 10.1002/ajh.25674

Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas

Foss¹, FM; Horwitz, SM; Civallero, M; Bellei, M; Marcheselli, L; Kim, WS; Cabrera, ME; Dlouhy, I; Nagler, A; Advani, RH; Pesce, EA; Ko, YH; Montoto, S; Chiattone, C; Moskowitz, A; Spina, M; Cesaretti, M; Biasoli, I; Federico, M

MEDICINE 2019 10.1097/MD.0000000000017641

Changing trends in lymphoid neoplasm distribution in South Korea: analysis of 8615 cases from a single institute, 1997-2016 An observational study

Sim¹, J; Takayama, T; Cho, J; Kim, SJ; Kim, WS; Ree, HJ; Ko, YH

BMC CANCER 2019 10.1186/s12885-019-6303-z

Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma

Kim¹, SJ; Yoon, DH; Kang, HJ; Hong, JY; Lee, HS; Oh, SY; Shin, HJ; Kong, JH; Yi, JH; Sakamoto, K; Ko, YH; Huh, J; Lee, SS; Takeuchi, K; Shin, DY; Suh, C; Kim, WS

INT J HEMATOL 2019 10.1007/s12185-019-02693-z

The Glasgow Prognostic Score is a significant predictor of peripheral T-cell lymphoma (PTCL) treated with CHOP-based chemotherapy and comparable with PTCL prognostic scores

Huh¹, S; Oh, SY; Lee, S; Lee, JH; Kim, SH; Lee, GW; Kim, SJ; Kim, WS; Lee, HS; Jo, JC; Kim, MJ; Kwon, JH; Kim, HJ

CANCER RES TREAT 2019 10.4143/crt.2018.555

Body Cavity- Based Lymphoma in a Country with Low Human Immunodeficiency Virus Prevalence: A Series of 17 Cases from the Consortium for Improving Survival of Lymphoma

Shin¹, J; Ko, YH; Oh, SY; Yoon, DH; Lee, JO; Kim, JS; Park, Y; Shin, HJ; Kim, SJ; Won, JH; Yoon, SS; Kim, WS; Koh, Y

BMC CANCER 2019 10.1186/s12885-019-6057-7

Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma

Kim¹, JH; Kim, WS; Park, C

SCI REP-UK 2019 10.1038/s41598-019-51522-0

A clinicohaematological prognostic model for nasal-type natural killer/T-cell lymphoma: A multicenter study

Tan¹, KM; Chia, B; Lim, JQ; Khoo, LP; Cheng, CL; Tan, L; Poon, E; Somasundaram, N; Farid, M; Tang, TPL; Tao, M; Cheah, DMZ; Laurensia, Y; Pang, JWL; Song, T; Tan, J; Huang, DC; Kim, SJ; Kim, WS; Ong, CK; Lim, ST; Chan, JY

CANCER COMMUN 2019 10.1186/s40880-019-0403-7

Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study

Oh¹, SY; Kim, WS; Kim, JS; Kim, SJ; Yoon, DH; Yang, DH; Lee, WS; Kim, HJ; Yhim, HY; Jeong, SH; Won, JH; Lee, S; Kong, JH; Lim, SN; Ji, JH; Kwon, KA; Lee, GW; Lee, JH; Lee, HS; Shin, HJ; Suh, C

LEUKEMIA LYMPHOMA 2019 10.1080/10428194.2019.1573998

Analysis of circulating tumor DNA by targeted ultra-deep sequencing across various non-Hodgkin lymphoma subtypes

Shin¹, SH; Kim, YJ; Lee, D; Cho, D; Ko, YH; Cho, J; Park, WY; Park, D; Kim, SJ; Kim, WS

LEUKEMIA LYMPHOMA 2019 10.1080/10428194.2019.1622100

A phase II trial of bendamustine, carboplatin, and dexamethasone for refractory or relapsed peripheral T-cell lymphoma (BENCART trial)

Park¹, BB; Kim, WS; Suh, C; Hong, JY; Yang, DH; Lee, WS; Do, YR; Koh, YI; Won, JH; Kim, MK; Jo, JC; Hyun, SY; Kim, JA; Oh, YH; Lee, SS

CANCER RES TREAT 2019 10.4143/crt.2018.191

Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus-Positive and -Negative Relapsed or Refractory Non-Hodgkin Lymphomas

Kim¹, SJ; Hyeon, J; Cho, I; Ko, YH; Kim, WS

CANCER RES TREAT 2019 10.4143/crt.2018.190

Radiation Therapy Outcome and Clinical Features of Duodenal-Type Follicular Lymphoma

Lee¹, H; Oh, D; Yang, K; Ko, YH; Ahn, YC; Kim, WS; Kim, SJ

CLIN LYMPHOMA MYELOMA LEUK 2019 10.1016/j.clml.2018.11.003

Multicenter Phase 2 Study of Reduced-Dose CHOP Chemotherapy Combined With Rituximab for Elderly Patients With Diffuse Large B-Cell Lymphoma

Park¹, S; Jo, JC; Do, YR; Yang, DH; Lim, SN; Lee, WS; Kim, WS; Lee, HS; Hong, DS; Kim, HJ; Shin, HJ

J CLIN ONCOL 2019 10.1200/JCO.18.00899

Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

O'Connor¹, OA; Ozcan, M; Jacobsen, ED; Roncero, JM; Trotman, J; Demeter, J; Masszi, T; Pereira, J; Ramchandren, R; Beaven, A; Caballero, D; Horwitz, SM; Lennard, A; Turgut, M; Hamerschlak, N; d'Amore, FA; Foss, F; Kim, WS; Leonard, JP; Zinzani, PL; Chiattone, CS; Hsi, ED; Trumper, L; Liu, H; Sheldon-Waniga, E; Ullmann, CD; Venkatakrishnan, K; Leonard, EJ; Shustov, AR

ANN HEMATOL 2019 10.1007/s00277-018-3516-1

Validation of the Marginal Zone Lymphoma International Prognostic Index

Hong¹, J; Cho, J; Ko, YH; Kim, SJ; Kim, WS

LEUKEMIA LYMPHOMA 2019 10.1080/10428194.2018.1480772

Serum IL18 is associated with hemophagocytosis and poor survival in extranodal natural killer/T-cell lymphoma

Lim¹, SW; Ryu, KJ; Lee, H; Ko, YH; Kim, WS; Kim, SJ

LANCET 2019 10.1016/S0140-6736(18)32984-2

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Horwitz¹, S; O'Connor, OA; Pro, B; Illidge, T; Fanale, M; Advani, R; Bartlett, NL; Christensen, JH; Morschhauser, F; Domingo-Domenech, E; Rossi, G; Kim, WS; Feldman, T; Lennard, A; Belada, D; Illes, A; Tobinai, K; Tsukasaki, K; Yeh, SP; Shustov, A; Huttmann, A; Savage, KJ; Yuen, S; Iyer, S; Zinzani, PL; Hua, ZW; Little, M; Rao, S; Woolery, J; Manley, T; Trumper, L; Aboulafia, D; Alpdogan, O; Ando, K; Arcaini, L; Baldini, L; Bellam, N; Bartlett, N; Ben Yehuda, D; Benedetti, F; Borchman, P; Bordessoule, D; Brice, P; Briones, J; Caballero, D; Carella, AM; Chang, H; Cheong, JW; Cho, SG; Choi, I; Choquet, S; Colita, A; Congui, AG; D'amore, F; Dang, N; Davison, K; De Guibert, S; Brown, PD; Delwail, V; Demeter, J; di Raimondo, F; Do, YR; Domingo, E; Douvas, M; Dreyling, M; Ernst, T; Fay, K; Ferrero, SF; Flinn, IW; Forero-Torres, A; Fox, C; Friedberg, J; Fukuhara, N; Garcia-Marco, J; Cruz, JG; Codina, JG; Gressin, R; Grigg, A; Gurion, R; Haioun, C; Hajek, R; Hanel, M; Hatake, K; Hensen, R; Horo

CYTOKINE 2019 10.1016/j.cyto.2018.10.009

Profiles of serum cytokines and their clinical implications in patients with peripheral T-cell lymphoma

Yi¹, JH; Ryu, KJ; Ko, YH; Kim, WS; Kim, SJ

BLOOD 2019 10.1182/blood-2018-04-848044

Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy

Kusumoto¹, S; Arcaini, L; Hong, XN; Jin, J; Kim, WS; Kwong, YL; Peters, MG; Tanaka, Y; Zelenetz, AD; Kuriki, H; Fingerle-Rowson, G; Nielsen, T; Ueda, E; Piper-Lepoutre, H; Sellam, G; Tobinai, K

CANCER SCI 2018 10.1111/cas.13844

Vitamin D deficiency is associated with inferior survival of patients with extranodal natural killer/T-cell lymphoma

Kim¹, SJ; Shu, C; Ryu, KJ; Kang, D; Cho, J; Ko, YH; Lee, SY; Guallar, E; Zhao, W; Kim, WS

BIOL BLOOD MARROW TR 2018 10.1016/j.bbmt.2018.07.034

Allogeneic Stem Cell Transplantation for Patients with Natural Killer/T Cell Lymphoid Malignancy: A Multicenter Analysis Comparing Upfront and Salvage Transplantation

Jeong¹, SH; Song, HN; Park, JS; Yang, DH; Koh, Y; Yoon, SS; Lee, HW; Eom, HS; Won, JH; Kim, WS; Kim, SJ

EUR J NUCL MED MOL I 2018 10.1007/s00259-018-4093-1

A risk stratification model for nodal peripheral T-cell lymphomas based on the NCCN-IPI and posttreatment Deauville score

Yhim¹, HY; Park, Y; Han, YH; Kim, S; Kang, SR; Moon, JH; Jeong, JH; Shin, HJ; Kim, K; Choi, YS; Kim, K; Kim, MK; Kong, E; Kim, DS; Eo, JS; Lee, JH; Kang, DY; Lee, WS; Lee, SM; Do, YR; Ham, JS; Kim, SJ; Kim, WS; Choi, JY; Yang, DH; Kwak, JY

ANN HEMATOL 2018 10.1007/s00277-018-3442-2

The cell-of-origin classification of diffuse large B cell lymphoma in a Korean population by the Lymph2Cx assay and its correlation with immunohistochemical algorithms

Hwang¹, HS; Yoon, DH; Hong, JY; Park, CS; Lee, YS; Ko, YH; Kim, SJ; Kim, WS; Suh, C; Huh, J

J HEMATOL ONCOL 2018 10.1186/s13045-018-0687-0

Treatment of localized extranodal NK/T cell lymphoma, nasal type: a systematic review

Kim¹, SJ; Yoon, SE; Kim, WS

Lancet Haematol 2018 10.1016/S2352-3026(18)30157-1

Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial

Ogura¹, M; Sancho, JM; Cho, SG; Nakazawa, H; Suzumiya, J; Tumyan, G; Kim, JS; Lennard, A; Mariz, J; Ilyin, N; Jurczak, W; Martinez, AL; Samoilova, O; Zhavrid, E; Ruiz, EY; Trneny, M; Popplewell, L; Coiffier, B; Buske, C; Kim, WS; Lee, SJ; Lee, SY; Bae, YJ; Kwak, LW

CANCER RES TREAT 2018 10.4143/crt.2017.207

Health-Related Quality of Life in Non-Hodgkin Lymphoma Survivors: A Prospective Cohort Study

Kang¹, D; Cho, J; Kim, IR; Kim, MK; Kim, WS; Kim, SJ

INVEST NEW DRUG 2018 10.1007/s10637-018-0582-0

Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy

Cho¹, H; Yoon, DH; Kim, KP; Bae, KS; Kim, WS; Eom, HS; Kim, JS; Hong, JY; Kim, SJ; Lee, H; Kim, SJ; Suh, C

ANN HEMATOL 2018 10.1007/s00277-018-3387-5

Treating synchronous bilateral ocular adnexal marginal zone lymphoma: the consortium for improving survival of lymphoma study

Oh¹, SY; Kim, WS; Kang, HJ; Lee, JH; Huh, S; Kim, S; Yoon, DH; Hong, JY; Lee, WS; Kim, HJ; Won, JH; Park, BB; Lee, SI; Suh, C

MODERN PATHOL 2018 10.1038/s41379-018-0064-0

Targeted deep sequencing of gastric marginal zone lymphoma identified alterations of TRAF3 and TNFAIP3 that were mutually exclusive for MALT1 rearrangement

Hyeon¹, J; Lee, B; Shin, SH; Yoo, HY; Kim, SJ; Kim, WS; Park, WY; Ko, YH

ANN HEMATOL 2018 10.1007/s00277-018-3313-x

Significance of circulating Epstein-Barr virus DNA monitoring after remission in patients with extranodal natural killer T cell lymphoma

Cho¹, J; Kim, SJ; Park, S; Yoo, KH; Ki, CS; Ko, Y; Kim, WS

BONE MARROW TRANSPL 2018 10.1038/s41409-018-0097-5

Satisfaction with sexual activity and sexual dysfunction in hematopoietic stem cell transplantation survivors and their partners: a couple study

Yoo¹, KH; Kang, D; Kim, IR; Choi, EK; Kim, JS; Yoon, SS; Lee, CH; Park, S; Kim, SJ; Kim, K; Kim, WS; Jung, CW; Choi, HJ; Jang, JH; Cho, J

ANN HEMATOL 2018 10.1007/s00277-018-3317-6

Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis

Hong¹, JY; Yoon, DH; Suh, C; Kim, WS; Kim, SJ; Jo, JC; Kim, JS; Lee, WS; Oh, SY; Park, Y; Kim, SY; Lee, MH; Lee, HS; Do, YR

HAEMATOL-HEMATOL J 2018 10.3324/haematol.2017.186577

The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project

Bellei¹, M; Foss, FM; Shustov, AR; Horwitz, SM; Marcheselli, L; Kim, WS; Cabrera, ME; Dlouhy, I; Nagler, A; Advani, RH; Pesce, EA; Ko, YH; Martinez, V; Montoto, S; Chiattone, C; Moskowitz, A; Spina, M; Biasoli, I; Manni, M; Federico, M

CANCER SCI 2018 10.1111/cas.13597

Early disease progression in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy

Yamaguchi¹, M; Suzuki, R; Kim, SJ; Ko, YH; Oguchi, M; Asano, N; Miyazaki, K; Terui, Y; Kubota, N; Maeda, T; Kobayashi, Y; Amaki, J; Soejima, T; Saito, B; Shimoda, E; Fukuhara, N; Tsukamoto, N; Shimada, K; Choi, I; Utsumi, T; Ejima, Y; Kim, WS; Katayama, N

BRIT J HAEMATOL 2018 10.1111/bjh.15258

Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network

Federico¹, M; Bellei, M; Marcheselli, L; Schwartz, M; Manni, M; Tarantino, V; Pileri, S; Ko, YH; Cabrera, ME; Horwitz, S; Kim, WS; Shustov, A; Foss, FM; Nagler, A; Carson, K; Pinter-Brown, LC; Montoto, S; Spina, M; Feldman, TA; Lechowicz, MJ; Smith, SM; Lansigan, F; Gabus, R; Vose, JM; Advani, RH

CANCER RES TREAT 2018 10.4143/crt.2017.182

Low-Dose Radiation Therapy for Primary Conjunctival Marginal Zone B-Cell

Lee¹, GI; Oh, D; Kim, WS; Kim, SJ; Ko, YH; Woo, KI; Kim, YD; Ahn, YC

Eur J Oncol Nurs 2018 10.1016/j.ejon.2018.01.012

Use of complementary and alternative medicine by lymphoma survivors in South Korea

Kim¹, K; Kim, SH; Ok, ON; Kim, IR; Lee, S; Kim, SH; Kim, WS; Ryu, MH; Lee, MH

ANN ONCOL 2018 10.1093/annonc/mdx764

Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial

Witzig¹, TE; Tobinai, K; Rigacci, L; Ikeda, T; Vanazzi, A; Hino, M; Shi, Y; Mayer, J; Costa, LJ; Silva, CDB; Zhu, J; Belada, D; Bouabdallah, K; Kattan, JG; Kuruvilla, J; Kim, WS; Larouche, JF; Ogura, M; Ozcan, M; Fayad, L; Wu, C; Fan, J; Louveau, AL; Voi, M; Cavalli, F

HUM PATHOL 2018 10.1016/j.humpath.2017.12.006

Identification of T-cell receptor expression in EBV-positive neoplastic cells in extranodal NK/T-cell lymphoma, nasal-type, and comparison with T-cell receptor gene rearrangement by BIOMED-2 assay

Takayama¹, T; Shin, S; Kang, S; Kim, SJ; Kim, WS; Ko, YH

Blood Cancer J 2018 10.1038/s41408-018-0056-9

CXCR4 can induce PI3K delta inhibitor resistance in ABC DLBCL

Kim¹, JH; Kim, WS; Ryu, KJ; Kim, SJ; Park, C

NEW ENGL J MED 2018 10.1056/NEJMoa1708984

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma

Connors¹, JM; Jurczak, W; Straus, DJ; Ansell, SM; Kim, WS; Gallamini, A; Younes, A; Alekseev, S; Illes, A; Picardi, M; Lech-Maranda, E; Oki, Y; Feldman, T; Smolewski, P; Savage, KJ; Bartlett, NL; Walewski, J; Chen, R; Ramchandren, R; Zinzani, PL; Cunningham, D; Rosta, A; Josephson, NC; Song, E; Sachs, J; Liu, R; Jolin, HA; Huebner, D; Radford, J

ANN ONCOL 2018 10.1093/annonc/mdx684

Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/IINK/T-cell lymphoma

Kwong¹, YL; Kim, SJ; Tse, E; Oh, SY; Kwak, JY; Eom, HS; Do, YR; Mun, YC; Lee, SR; Shin, HJ; Suh, C; Chuang, SS; Lee, YS; Lim, ST; Izutsu, K; Suzuki, R; Relander, T; d'Amore, F; Schmitz, N; Jaccard, A; Kim, WS

CANCER RES TREAT 2018 10.4143/crt.2017.091

Validation of the Korean Version of the Quality of Life-Cancer Survivors (QOL-CS-K) Questionnaire in Lymphoma Survivors

Cho¹, J; Kang, D; Kim, IR; Kim, WS; Ferrell, B; Kim, SJ

J CLIN ONCOL 2017 10.1200/JCO.2017.75.4648

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma

Dreyling¹, M; Santoro, A; Mollica, L; Leppa, S; Follows, GA; Lenz, G; Kim, WS; Nagler, A; Panayiotidis, P; Demeter, J; Ozcan, M; Kosinova, M; Bouabdallah, K; Morschhauser, F; Stevens, DA; Trevarthen, D; Giurescu, M; Cupit, L; Liu, L; Kochert, K; Seidel, H; Pena, C; Yin, SX; Hiemeyer, F; Garcia-Vargas, J; Childs, BH; Zinzani, PL

HAEMATOL-HEMATOL J 2017 10.3324/haematol.2017.169656

Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma

Younes¹, A; Salles, G; Martinelli, G; Bociek, RG; Barrigon, DC; Barca, EG; Turgut, M; Gerecitano, J; Kong, O; Pisal, CB; Tavorath, R; Kim, WS

HEMATOL ONCOL 2017 10.1002/hon.2316

Pitfalls and major issues in the histologic diagnosis of peripheral T-cell lymphomas: results of the central review of 573 cases from the T-Cell Project, an international, cooperative study

Bellei¹, M; Sabattini, E; Pesce, EA; Ko, YH; Kim, WS; Cabrera, ME; Martinez, V; Dlouhy, I; Paes, RP; Barrese, T; Vassallo, J; Tarantino, V; Vose, J; Weisenburger, D; Rudiger, T; Federico, M; Pileri, S

HEMATOL ONCOL 2017 10.1002/hon.2316

Pitfalls and major issues in the histologic diagnosis of peripheral T-cell lymphomas: results of the central review of 573 cases from the T-Cell Project, an international, cooperative study

Bellei¹, M; Sabattini, E; Pesce, EA; Ko, YH; Kim, WS; Cabrera, ME; Martinez, V; Dlouhy, I; Paes, RP; Barrese, T; Vassallo, J; Tarantino, V; Vose, J; Weisenburger, D; Rudiger, T; Federico, M; Pileri, S

Blood Cancer J 2017 10.1038/s41408-017-0030-y

Outcomes of patients with peripheral T-cell lymphoma in first complete remission: data from three tertiary Asian cancer centers

Tang¹, T; Khoo, LP; Lim, C; Ham, JS; Kim, SJ; Hong, HM; Phipps, C; Lee, YS; Tao, M; Quek, R; Farid, M; Lin, TY; Kim, WS; Lim, ST

HEMATOL ONCOL 2017 10.1002/hon.2374

Serum level of CXCL10 is associated with inflammatory prognostic biomarkers in patients with diffuse large B-cell lymphoma

Hong¹, JY; Ryu, KJ; Lee, JY; Park, C; Ko, YH; Kim, WS; Kim, SJ

HEMATOL ONCOL 2017 10.1002/hon.2374

Serum level of CXCL10 is associated with inflammatory prognostic biomarkers in patients with diffuse large B-cell lymphoma

Hong¹, JY; Ryu, KJ; Lee, JY; Park, C; Ko, YH; Kim, WS; Kim, SJ

ONCOTARGET 2017 10.18632/oncotarget.20988

Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma

Hong¹, J; Kim, SJ; Chang, MH; Kim, JA; Kwak, JY; Kim, JS; Yoon, DH; Lee, WS; Do, YR; Kang, HJ; Eom, HS; Park, Y; Won, JH; Mun, YC; Kim, HJ; Kwon, JH; Kong, JH; Oh, SY; Lee, S; Bae, SH; Yang, DH; Jun, HJ; Lee, HS; Yun, HJ; Lee, SI; Kim, MK; Yi, JH; Lee, JH; Kim, WS; Suh, C

J INFECT CHEMOTHER 2017 10.1016/j.jiac.2017.04.004

Atypical presentations of MERS-CoV infection in immunocompromised hosts

Kim¹, SH; Ko, JH; Park, GE; Cho, SY; Ha, YE; Kang, JM; Kim, YJ; Huh, HJ; Ki, CS; Jeong, BH; Park, J; Jang, JH; Kim, WS; Kang, CI; Chung, DR; Song, JH; Peck, KR

JPN J CLIN ONCOL 2017 10.1093/jjco/hyx120

Whole brain radiation dose reduction for primary central nervous system lymphoma patients who achieved partial response after high-dose methotrexate based chemotherapy

Park¹, JS; Lim, DH; Ahn, YC; Park, W; Kim, SJ; Kim, WS; Kim, K

J CLIN ONCOL 2017 10.1200/JCO.2017.73.3402

Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma

Vitolo¹, U; Trneny, M; Belada, D; Burke, JM; Carella, AM; Chua, N; Abrisqueta, P; Demeter, J; Flinn, I; Hong, X; Kim, WS; Pinto, A; Shi, YK; Tatsumi, Y; Oestergaard, MZ; Wenger, M; Fingerle-Rowson, G; Catalani, O; Nielsen, T; Martelli, M; Sehn, LH

LEUKEMIA LYMPHOMA 2017 10.1080/10428194.2017.1298752

Report of the 6th International Workshop on PET in lymphoma

Nanni¹, C; Cottereau, AS; Lopci, E; Bodet-Milin, C; Coronado, M; Pro, B; Kim, WS; Trotman, J; Barrington, S; Duhrsen, U; Vander Borght, T; Zamagni, E; Kraeber-Bodere, F; Messiou, C; Rahmouni, A; Buvat, I; Andre, M; Hertzberg, M; Oyen, W; Casasnovas, O; Luminari, S; Garderet, L; Montravers, F; Kobe, C; Kluge, R; Versari, A; Zucca, E; Moreau, P; Cheson, B; Haioun, C; Gallamini, A; Meignan, M

Lancet Haematol 2017

Research on Biosimilars: pivotal trials and principles

Jurczak¹, W; Vulto, AG; Amersdorffer, J; Kim, WS; Coiffier, B

ONCOTARGET 2017 10.18632/oncotarget.19301

Elevated serum interleukin-10 level and M2 macrophage infiltration are associated with poor survival in angioimmunoblastic T-cell lymphoma

Ham¹, JS; Park, HY; Ryu, KJ; Ko, YH; Kim, WS; Kim, SJ

KOREAN JOURNAL OF INTERNAL MEDICINE 2017 10.3904/kjim.2015.406

Clinical features and treatment outcomes of blastic plasmacytoid dendritic cell neoplasm: a single-center experience in Korea

Kim¹, HS; Kim, HJ; Kim, SH; Choi, JY; Ko, YH; Kim, WS; Jung, CW; Kim, SJ

ANN ONCOL 2017 10.1093/annonc/mdx316

Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease

Lim¹, SH; Hong, JY; Lim, ST; Hong, H; Arnoud, J; Zhao, W; Yoon, DH; Tang, T; Cho, J; Park, S; Ko, YH; Kim, SJ; Suh, C; Lin, T; Kim, WS

HEMATOL ONCOL 2017 10.1002/hon.2283

Macrophage inflammatory protein 1 alpha (MIP-1) may be associated with poor outcome in patients with extranodal NK/T-cell lymphoma

Kim¹, HS; Ryu, KJ; Ko, YH; Kim, HJ; Kim, SH; Kim, WS; Kim, SJ

Lancet Haematol 2017 10.1016/S2352-3026(17)30120-5

Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial

Kim¹, WS; Buske, C; Ogura, M; Jurczak, W; Sancho, JM; Zhavrid, E; Kim, JS; Hernandez-Rivas, JA; Prokharau, A; Vasilica, M; Nagarkar, R; Osmanov, D; Kwak, LW; Lee, SJ; Lee, SY; Bae, YJ; Coiffier, B

Leuk Lymphoma. 2017 Jun;58(6):1341-1348. doi: 10.1080/10428194.2016.1236380. Epub 2016 Oct 9.

Value of interim FDG PET/CT for predicting outcome of patients with angioimmunoblastic T-cell lymphoma

Moon SH1¹, Lee AY1, Kim WS2, Kim SJ2, Cho YS1, Choe YS1, Kim BT1, Lee KH1.

Nutrition. 2017 Apr;36:67-71. doi: 10.1016/j.nut.2016.06.009. Epub 2016 Jun 25.

Patient-Generated Subjective Global Assessment as a prognosis tool in patients with multiple myeloma

Kim HS1¹, Lee JY2, Lim SH2, Cho J3, Kim SJ2, Jang JH2, Kim WS2, Jung CW2, Kim K4.

Oncotarget. 2017 Mar 7;8(10):17038-17049. doi: 10.18632/oncotarget.14928.

The mutational landscape of ocular marginal zone lymphoma identifies frequent alterations in TNFAIP3 followed by mutations in TBL1XR1 and CREBBP

Jung H1¹,2, Yoo HY3, Lee SH3, Shin S4, Kim SC1, Lee S1, Joung JG1, Nam JY1,3, Ryu D1,3, Yun JW1,5, Choi JK2, Ghosh A5, Kim KK5, Kim SJ6, Kim WS6, Park WY1, Ko YH4.

Oncotarget. 2017 Mar 28;8(13):22014-22022. doi: 10.18632/oncotarget.15782.

Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm

Yoon N1¹, Ahn S2, Yong Yoo H3, Jin Kim S4, Seog Kim W4, Hyeh Ko Y5.

J Clin Oncol. 2016 Dec 28:JCO2016690198.

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study

van Imhoff GW1¹, McMillan A1, Matasar MJ1, Radford J1, Ardeshna KM1, Kuliczkowski K1, Kim W1, Hong X1, Goerloev JS1, Davies A1, Barrigon MD1, Ogura M1, Leppa S1, Fennessy M1, Liao Q1, van der Holt B1, Lisby S1, Hagenbeek A1.

Oncotarget. 2017 Feb 21;8(8):13782-13791. doi: 10.18632/oncotarget.14636.

Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab-CHOP

Hong JY1¹, Ryu KJ2, Park C3, Hong M4, Ko YH5, Kim WS6, Kim SJ2,6.

Oncotarget. 2017 Jan 10;8(2):2466-2476. doi: 10.18632/oncotarget.13690.

FOXO4 expression is related to stem cell-like properties and resistance to treatment in diffuse large B-cell lymphoma

Ryu KJ1¹, Park C2, Hong M3, Ko YH4, Kim WS5, Kim SJ1,5.

Mod Pathol. 2017 Jan;30(1):4-14. doi: 10.1038/modpathol.2016.56. Epub 2016 Sep 30.

Prognostic impact of MYC protein expression in central nervous system diffuse large B-cell lymphoma: comparison with MYC rearrangement and MYC mRNA expression

Son SM1¹, Ha SY1, Yoo HY2,3, Oh D4, Kim SJ3,5, Kim WS3,5, Ko YH1,3.

ONCOTARGET, JAN 17 2017, 8(3):5361-5370, DOI: 10.18632/oncotarget.14243

Epstein-Barr virus EBNA2 directs doxorubicin resistance of B cell lymphoma through CCL3 and CCL4-mediated activation of NF-kappa B and Btk

Kim JH¹, Kim WS, Hong JY, Ryu KJ, Kim SJ, Park C

Cancer Res Treat. 2017 Jan;49(1):92-103. doi: 10.4143/crt.2015.476. Epub 2016 May 9.

Comparison of Total Body Irradiation (TBI) Conditioning with Non-TBI for Autologous Stem Cell Transplantation in Newly Diagnosed or Relapsed Mature T- and NK-Cell Non-Hodgkin Lymphoma

Maeng CH1¹, Ko YH2, Lim DH3, Kang ES4, Choi JY5, Kim WS6, Kim SJ6,7.

Ann Lab Med. 2016 May;36(3):209-14. doi: 10.3343/alm.2016.36.3.209.

Usefulness of Flow Cytometric Analysis for Detecting Leptomeningeal Diseases in Non-Hodgkin Lymphoma

Shin SY1¹,2, Lee ST2,3, Kim HJ2, Oh YL4, Kim SJ5, Kim WS5, Kim SH6.

Clin Lymphoma Myeloma Leuk. 2016 Apr;16(4):197-202. doi: 10.1016/j.clml.2015.12.012. Epub 2016 Jan 6.

Clinical Features and Survival of Patients With Follicular Lymphoma in Korea

Cho SH1¹, Suh C2, Do YR3, Lee JJ4, Yun HJ5, Oh SY6, Lee HS7, Cho SG8, Cho IS9, Lee WS10, Won YW11, Kim HJ12, Lee HG13, Lee SI14, Lim SN15, Sohn BS16, Ahn HJ17, Chang MH18, Kwon KA19, Kim WS20.

Cancer Chemother Pharmacol. 2016 Apr;77(4):865-73. doi: 10.1007/s00280-016-3005-y. Epub 2016 Mar 16.

Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis

Shin DY1¹, Kim SJ2, Yoon DH3, Park Y4, Kong JH5, Kim JA6, Kim BS7, Kim HJ8, Won JH9, Park SK10, Kim WS11.

Lancet Oncol. 2016 Mar;17(3):389-400. doi: 10.1016/S1470-2045(15)00533-1. Epub 2016 Feb 10.

A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis

Kim SJ1¹, Yoon DH2, Jaccard A3, Chng WJ4, Lim ST5, Hong H6, Park Y7, Chang KM8, Maeda Y9, Ishida F10, Shin DY11, Kim JS12, Jeong SH13, Yang DH14, Jo JC15, Lee GW16, Choi CW17, Lee WS18, Chen TY19, Kim K20, Jung SH20, Murayama T21, Oki Y22, Advani R23, d'Amore F24, Schmitz N25, Suh C2, Suzuki R26, Kwong YL27, Lin TY6, Kim WS28.

Ann Oncol. 2016 Mar;27(3):508-13. doi: 10.1093/annonc/mdv596. Epub 2015 Dec 9.

Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin

Kim SJ1¹, Kim JH2, Ki CS3, Ko YH4, Kim JS5, Kim WS6.

Ann Hematol. 2016 Mar;95(4):581-91. doi: 10.1007/s00277-015-2581-y. Epub 2016 Jan 4.

Extra-nodal natural killer/T cell lymphoma in elderly patients: the impact of aging on clinical outcomes and treatment tolerability

Kim SM1¹, Park S1, Oh DR2, Ahn YC2, Ko YH3, Kim SJ1, Kim WS4.

Ann Hematol. 2016 Mar;95(4):603-11. doi: 10.1007/s00277-016-2589-y. Epub 2016 Jan 11.

Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy: the Korean multicenter retrospective study

Kim JS1¹, Yoon DH2, Park S3, Yoon SS3, Cho SG4, Min CK4, Lee JJ5, Yang DH5, Kwak JY6, Eom HS7, Kim WS8, Kim H9, Do YR10, Moon JH11, Lee J12, Suh C13.

Blood Cancer J. 2016 Feb 12;6:e395. doi: 10.1038/bcj.2016.2.

The prognostic value of interim and end-of-treatment PET/CT in patients with newly diagnosed peripheral T-cell lymphoma

Ham JS1¹, Kim SJ1, Choi JY2, Hyun SH2, Choi SK3, Kim HS1, Lim SH1, Lee JY1, Jung SH3, Ko YH4, Kim WS1.

Oncotarget. 2016 Dec 27;7(52):86433-86445. doi: 10.18632/oncotarget.13239.

Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma

Park HY1¹,2, Lee SB3, Yoo HY4, Kim SJ5, Kim WS5, Kim JI1, Ko YH2.

Oncotarget. 2016 Dec 20;7(51):85584-85591. doi: 10.18632/oncotarget.11319.

Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL1008)

Yoon DH1¹, Kim SJ2, Jeong SH3, Shin DY4, Bae SH5, Hong J6, Park SK7, Yhim HY8, Yang DH9, Lee H10, Kang HJ11, Lee MH12, Eom HS10, Kwak JY8, Lee JH6, Suh C1, Kim WS2.

Int J Hematol. 2016 Nov;104(5):591-595. Epub 2016 Jul 25.

Clinical features and treatment outcome of Epstein-Barr virus-positive nodal T-cell lymphoma

Jung KS1¹,2, Cho SH2, Kim SJ1, Ko YH3, Kim WS4.

Oncotarget. 2016 Nov 22;7(47):76934-76943. doi: 10.18632/oncotarget.12734.

Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era

Seo S1¹, Hong JY1, Yoon S1,2, Yoo C1, Park JH1, Lee JB3, Park CS4, Huh J5, Lee Y5, Kim KW6, Ryu JS7, Kim SJ8, Kim WS8, Yoon DH1, Suh C1.

Ann Oncol. 2016 Nov;27(11):2133-2134. Epub 2016 Aug 8.

Reply to the letter to the editor 'Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin, histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma' by Tan et al.

Kim SJ1¹,2, Kim WS3.

J Infect. 2016 Nov;73(5):496-505. doi: 10.1016/j.jinf.2016.06.011. Epub 2016 Jul 7.

Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients

Park S1¹, Kim K1, Jang JH1, Kim SJ1, Kim WS1, Chung DR2, Kang CI2, Peck KR2, Jung CW3.

Oncotarget. 2016 Nov 1;7(44):72033-72043. doi: 10.18632/oncotarget.12459.

Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study

Kim SJ1¹, Hong JS2, Chang MH3, Kim JA4, Kwak JY5, Kim JS6, Yoon DH7, Lee WS8, Do YR9, Kang HJ10, Eom HS11, Park Y12, Won JH13, Mun YC14, Kim HJ15, Kwon JH16, Kong JH17, Oh SY18, Lee S19, Bae SH20, Yang DH21, Jun HJ22, Kim YS23, Yun HJ24, Lee SI25, Kim MK26, Park EK27, Kim WS1, Suh C7.

Ann Hematol. 2016 Jan;95(2):325-35. doi: 10.1007/s00277-015-2523-8. Epub 2015 Oct 10.

Clinical significance of bone marrow hemophagocytosis in adult patients with malignancy and non-malignancy-induced hemophagocytic lymphohistiocytosis

Lim SH1¹, Park S1, Jang JH1, Kim K1, Kim HJ2, Kim SH2, Kang CI3, Chung DR3, Peck KR3, Lee J4, Cha HS4, Koh EM4, Ko YH5, Kim WS1, Jung CW1, Kim SJ6,7.

Cancer Res Treat. 2016 Jan;48(1):312-21. doi: 10.4143/crt.2014.266. Epub 2015 Mar 2.

Cross-sectional Study of Patients with Diffuse Large B-Cell Lymphoma: Assessing the Effect of Host Status, Tumor Burden, and Inflammatory Activity on Venous Thromboembolism

Lim SH1¹, Woo SY2, Kim S2, Ko YH3, Kim WS1, Kim SJ1.

Oncotarget. 2016 Sep 13;7(37):59892-59901. doi: 10.18632/oncotarget.10988.

Blood concentration of cyclosporine during early post-transplant period may have influence on the occurrence of chronic graft versus host disease in patients who received allogeneic hematopoietic stem cell transplantation

Park S1¹, Kim K1, Jang JH1, Kim SJ1, Kim WS1, Jung CW1.

Acta Haematol. 2016;136(3):186-90. doi: 10.1159/000448159. Epub 2016 Sep 14.

Mediastinal Gray Zone Lymphoma with Features Intermediate between Classical Hodgkin Lymphoma and Primary Mediastinal B-Cell Lymphoma

Song HN1¹, Kim SJ, Ko YH, Kim WS.

INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2016, 9(6):8745-8749

Multifocal lymphadenopathy due to cytomegalovirus and Epstein-Barr virus infection in lymphoma patients receiving chemotherapy: a report of two cases

Son SM¹, Choi M, Kim WS, Ko YH

Haematologica. 2016 Jun;101(6):757-63. doi: 10.3324/haematol.2015.139253. Epub 2016 Jan 27.

Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma

Yoo HY1¹, Kim P2, Kim WS3, Lee SH4, Kim S5, Kang SY6, Jang HY7, Lee JE7, Kim J8, Kim SJ3, Ko YH9, Lee S10.

Leuk Lymphoma. 2016;57(6):1413-22. doi: 10.3109/10428194.2015.1113276. Epub 2015 Dec 24.

CD79B limits response of diffuse large B cell lymphoma to ibrutinib

Kim JH1¹, Kim WS1,2, Ryu K1, Kim SJ1,2, Park C1.

Leuk Lymphoma. 2016;57(6):1406-12. doi: 10.3109/10428194.2015.1099650. Epub 2015 Nov 16.

A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial

Oh SY1¹, Kim WS2, Kim JS3, Chae YS4, Lee GW5, Eom HS6, Ryoo HM7, Lee S1, Kim SJ2, Yoon DH8, Won JH9, Hong J10, Park J10, Lee SM11, Hong JY12, Park E12, Kim HJ13, Yang DH14, Kim HJ1, Suh C8.

Haematologica. 2016 Jun;101(6):e271. doi: 10.3324/haematol.2016.148015. Epub 2016 May 31.

Author reply to Comment on: Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma, by Yoo et al.

Yoo HY1¹, Kim P2, Kim WS3, Lee SH1, Kim S4, Kang SY5, Jang HY6, Lee JE6, Kim J7, Kim SJ3, Ko YH8, Lee S9.

Bone Marrow Transplant. 2016 Jun;51(6):807-12. doi: 10.1038/bmt.2016.6. Epub 2016 Feb 8.

Prognostic relevance of pretransplant Deauville score on PET-CT and presence of EBV DNA in patients who underwent autologous stem cell transplantation for ENKTL

Lim SH1¹, Hyun SH2, Kim HS1, Lee JY1, Yoo KH1, Jung KS1, Song HN1, Cho J1, Park S1, Ko YH3, Kim SJ1, Choi JY2, Kim WS1.

Mod Pathol. 2016 May;29(5):430-43. doi: 10.1038/modpathol.2016.47. Epub 2016 Mar 25.

Nasal-type NK/T-cell lymphomas are more frequently T rather than NK lineage based on T-cell receptor gene, RNA, and protein studies: lineage does not predict clinical behavior

Hong M1¹,2, Lee T1, Young Kang S1, Kim SJ3, Kim W3, Ko YH1.

Korean J Intern Med. 2016 May;31(3):560-9. doi: 10.3904/kjim.2014.222. Epub 2016 Feb 22.

Treatment outcomes and clinical relevance of the Follicular Lymphoma International Prognostic Index in Korean follicular lymphoma patients treated with chemotherapy

Maeng CH1¹,2, Ahn SW3, Ryu SY3, Han S3, Ko YH4, Ji JH5, Kim WS2, Kim SJ2.

J Hematol Oncol. 2016 Apr 18;9:41. doi: 10.1186/s13045-016-0271-4.

L-asparaginase-based regimens followed by allogeneic hematopoietic stem cell transplantation improve outcomes in aggressive natural killer cell leukemia

Jung KS1¹,2, Cho SH2, Kim SJ1, Ko YH3, Kang ES4, Kim WS5.

Ann Oncol. 2016 Apr;27(4):712-8. doi: 10.1093/annonc/mdv624. Epub 2016 Feb 8.

A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas

Kim SJ1¹, Shin DY2, Kim JS3, Yoon DH4, Lee WS5, Lee H6, Do YR7, Kang HJ2, Eom HS6, Ko YH8, Lee SH9, Yoo HY10, Hong M11, Suh C4, Kim WS12.

Oncotarget. 2016 Mar 15;7(11):12359-71. doi: 10.18632/oncotarget.7132.

Clonal relationships in recurrent B-cell lymphomas

Lee SE1¹, Kang SY2, Yoo HY3, Kim SJ4, Kim WS4, Ko YH2.

Ann Oncol. 2015 Sep;26 Suppl 5:v108-15. doi: 10.1093/annonc/mdv201.

Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(aEuro)

d'Amore F1¹, Gaulard P2, Trumper L3, Corradini P4, Kim WS5, Specht L6, Bjerregaard Pedersen M1, Ladetto M7; ESMO Guidelines Committee.

Hum Immunol. 2015 Sep;76(9):636-43. doi: 10.1016/j.humimm.2015.09.009. Epub 2015 Sep 25.

KIR alloreactivity based on the receptor-ligand model is associated with improved clinical outcomes of allogeneic hematopoietic stem cell transplantation: Result of single center prospective study

Park S1¹, Kim K1, Jang JH1, Kim SJ1, Kim WS1, Kang ES2, Jung CW3.

Curr Opin Oncol. 2015 Sep;27(5):392-8. doi: 10.1097/CCO.0000000000000210.

Epstein - Barr virus-positive diffuse large B-cell lymphoma of the elderly: a concise review and update

Hong JY1¹, Ko YH, Kim SJ, Kim WS.

Lancet Haematol. 2015 Aug;2(8):e326-33. doi: 10.1016/S2352-3026(15)00097-6. Epub 2015 Jul 7.

Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial

Tan D1¹, Phipps C2, Hwang WY2, Tan SY3, Yeap CH2, Chan YH4, Tay K5, Lim ST5, Lee YS2, Kumar SG2, Ng SC6, Fadilah S7, Kim WS8, Goh YT9; SGH651 Investigators.

Int J Hematol. 2015 Dec;102(6):678-88.

Efficacy and feasibility of autologous stem cell transplantation in patients with diffuse large B-cell lymphoma with secondary central nervous system involvement

Lee MY¹, Kim HS, Lee JY, Lim SH, Kang ES, Ko YH, Kim SJ, Kim WS.

Oncotarget. 2015 Dec 15;6(40):42803-12. doi: 10.18632/oncotarget.5658.

Iron deficient erythropoiesis might play key role in development of anemia in cancer patients

Park S1¹, Jung CW1, Kim K1, Kim SJ1, Kim WS1, Jang JH1.

Ann Hematol. 2015 Nov;94(11):1845-51. doi: 10.1007/s00277-015-2468-y. Epub 2015 Aug 8.

Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial

Park BB1¹, Kim WS2, Suh C3, Shin DY4, Kim JA5, Kim HG6, Lee WS7.

APMIS. 2015 Nov;123(11):990-2. doi: 10.1111/apm.12458.

Systemic Epstein-Barr virus-negative mature natural killer-cell lymphoma with cutaneous and visceral involvement

Kim HS1¹, Lee HW2, Kim WS3, Ko YH4.

Liver Int. 2015 Nov;35(11):2363-9. doi: 10.1111/liv.12838. Epub 2015 Apr 12.

Hepatitis B reactivation in multiple myeloma patients with resolved hepatitis B undergoing chemotherapy

Lee JY1¹, Lim SH1, Lee MY1, Kim H1, Sinn DH1, Gwak GY1, Choi MS1, Lee JH1, Jung CW1, Jang JH1, Kim WS1, Kim SJ1, Kim K1.

Leuk Lymphoma. 2015;56(11):3052-7. doi: 10.3109/10428194.2015.1025391. Epub 2015 Apr 8.

A subset of CD45+/CD19-cells in bone marrow may be associated with clinical outcomes of patients with mantle cell lymphoma

Kim SM1¹, Lee ST2,3, Ryu KJ4, Kim HJ2, Kim SH2, Ko YH5, Kim WS1, Kim SJ1,6.

Haematologica. 2015 Dec;100(12):e505-7. doi: 10.3324/haematol.2015.133074. Epub 2015 Sep 24.

A highly recurrent novel missense mutation in CD28 among angioimmunoblastic T-cell lymphoma patients

Lee SH1¹, Kim JS1, Kim J2, Kim SJ3, Kim WS3, Lee S2, Ko YH4, Yoo HY5.

Int J Radiat Oncol Biol Phys. 2015 Nov 1;93(3):677-83. doi: 10.1016/j.ijrobp.2015.07.2267. Epub 2015 Jul 22.

Concurrent Chemoradiation Therapy Followed by Consolidation Chemotherapy for Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type

Oh D1¹, Ahn YC2, Kim SJ3, Kim WS3, Ko YH4.

Int J Hematol. 2015 Oct;102(4):420-5. doi: 10.1007/s12185-015-1845-6. Epub 2015 Jul 26.

Is there role of additional chemotherapy after definitive local treatment for stage I/II marginal zone lymphoma: Consortium for Improving Survival of Lymphoma (CISL) study

Koh MS1¹, Kim WS2, Kim SJ2, Oh SY3, Yoon DH4, Lee SI5, Hong J6, Song MK7, Shin HJ7, Kwon JH8, Kim HJ8, Do YR9, Suh C10, Kim HJ1.

Int Forum Allergy Rhinol. 2015 Oct;5(10):960-6. doi: 10.1002/alr.21564. Epub 2015 Jun 3.

Nasal endoscopic evaluation and its impact on survival in patients with stage I/II extranodal natural killer/T-cell lymphoma, nasal type

Cho HJ1¹, Jang MS2, Hong SD2, Kim SJ3, Ahn YC4, Oh D4, Ko YH5, Kim HY2, Dhong HJ2, Chung SK2, Kim WS3.

Transpl Infect Dis. 2015 Oct;17(5):679-87. doi: 10.1111/tid.12424. Epub 2015 Sep 26.

Incidence of infection according to intravenous immunoglobulin use in autologous hematopoietic stem cell transplant recipients with multiple myeloma

Park S1¹, Jung CW1, Jang JH1, Kim SJ1, Kim WS1, Kim K1.

Korean J Intern Med. 2015 Jan;30(1):88-95. doi: 10.3904/kjim.2015.30.1.88. Epub 2014 Dec 30.

The efficacy of low-dose transdermal fentanyl in opioid-naive cancer patients with moderate-to-severe pain

Kang JH1¹, Oh SY2, Song SY3, Lee HY3, Kim JH4, Lee KE5, Lee HR6, Hwang IG7, Park SH8, Kim WS8, Park YS8, Park K8.

Biol Blood Marrow Transplant. 2015 Sep;21(9):1597-604. doi: 10.1016/j.bbmt.2015.05.003. Epub 2015 May 8.

Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell Lymphoma

Yhim HY1¹, Kim JS2, Mun YC3, Moon JH4, Chae YS4, Park Y5, Jo JC6, Kim SJ7, Yoon DH8, Cheong JW2, Kwak JY1, Lee JJ9, Kim WS7, Suh C8, Yang DH10; Consortium for Improving Survival of Lymphoma Study.

Invest New Drugs. 2015 Aug;33(4):942-53. doi: 10.1007/s10637-015-0258-y. Epub 2015 Jun 19.

Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose

Venkatakrishnan K1¹, Kim TM, Lin CC, Thye LS, Chng WJ, Ma B, Chen MH, Zhou X, Liu H, Kelly V, Kim WS.

Oncotarget. 2015 Jul 10;6(19):17764-76.

Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type

Lee S1¹, Park HY2, Kang SY3, Kim SJ4, Hwang J2, Lee S5, Kwak SH6, Park KS6,7, Yoo HY5, Kim WS4, Kim JI1,2,8, Ko YH3.

Cancer Res Treat. 2015 Jul;47(3):448-57. doi: 10.4143/crt.2014.034. Epub 2014 Nov 3.

Clinical Significance of Non-neutropenic Fever in the Management of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP: Comparison with Febrile Neutropenia and Risk Factor Analysis

Park S1¹, Kang CI2, Chung DR2, Peck KR2, Kim WS1, Kim SJ1.

Eur J Haematol. 2015 Jun;94(6):504-10. doi: 10.1111/ejh.12459. Epub 2014 Nov 21.

Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL)

Jung SH1¹, Lee JJ1, Kim WS2, Lee WS3, Do YR4, Oh SY5, Kim MK6, Mun YC7, Shin HJ8, Kwak JY9, Kang HJ10, Won JH11, Kwon JH12, Park E13, Suh C14, Yang DH1.

Genes Chromosomes Cancer. 2015 Jun;54(6):383-96. doi: 10.1002/gcc.22249. Epub 2015 Mar 31.

Integrated Copy Number and Gene Expression Profiling Analysis of Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma

Yoon H1¹, Park S, Ju H, Ha SY, Sohn I, Jo J, Do IG, Min S, Kim SJ, Kim WS, Yoo HY, Ko YH.

Anticancer Res. 2015 Jun;35(6):3333-40.

Microarray Gene-expression Profiling Analysis Comparing PCNSL and Non-CNS Diffuse Large B-Cell Lymphoma

Lim do H1¹, Kim WS2, Kim SJ3, Yoo HY4, Ko YH5.

J Hematol Oncol. 2015 May 14;8:49. doi: 10.1186/s13045-015-0142-4.

The serum CXCL13 level is associated with the Glasgow Prognostic Score in extranodal NK/T-cell lymphoma patients

Kim SJ1¹,2, Ryu KJ3, Hong M4, Ko YH5, Kim WS6.

Acta Neurochir (Wien). 2015 Apr;157(4):569-76. doi: 10.1007/s00701-015-2344-5. Epub 2015 Feb 8.

Optimal treatment of leptomeningeal spread in glioblastoma: analysis of risk factors and outcome

Noh JH1¹, Lee MH, Kim WS, Lim do H, Kim ST, Kong DS, Nam DH, Lee JI, Seol HJ.

Cancer Res Treat. 2015 Apr;47(2):173-81. doi: 10.4143/crt.2014.055. Epub 2014 Oct 28.

Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis

Hong J1¹, Kim SJ2, Ahn JS3, Song MK4, Kim YR5, Lee HS6, Yhim HY7, Yoon DH8, Kim MK9, Oh SY10, Park Y11, Mun YC12, Do YR13, Ryoo HM14, Lee JJ3, Lee JH1, Kim WS2, Suh C8.

Anticancer Res. 2015 Apr;35(4):2465-74.

The Clinical Significance of Activated p-AKT Expression in Peripheral T-cell Lymphoma

Hong JY1¹, Hong ME2, Choi MK3, Chang W4, Do IG5, Jo JS5, Jung SH6, Park S7, Kim SJ7, Ko YH2, Kim WS8.

Leuk Lymphoma. 2015 Apr;56(4):1020-6. doi: 10.3109/10428194.2014.946027. Epub 2014 Aug 20.

Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lymphoma

Lee GW1¹, Go SI, Kim SH, Hong J, Kim YR, Oh S, Kim SY, Do YR, Lee H, Lee SI, Bae SH, Oh SY, Song MK, Lee WS, Lee B, Kim JS, Kim MK, Kang HJ, Ahn JS, Yhim HY, Kim HJ, Kim SJ, Kim WS, Suh C; Consortium for Improving Survival of Lymphoma (CISL) study group.

Haematologica. 2015 Mar;100(3):e106-9. doi: 10.3324/haematol.2014.116087. Epub 2014 Dec 5.

Serum survivin and vascular endothelial growth factor in extranodal NK/T-cell lymphoma, nasal type: implications for a potential new prognostic indicator

Kim SJ1¹, Hong M2, Do IG2, Lee SH3, Ryu KJ4, Yoo HY5, Hong JY6, Ko YH2, Kim WS7.

Ann Oncol. 2015 Mar;26(3):548-55. doi: 10.1093/annonc/mdu556. Epub 2014 Dec 4.

EBV-positive diffuse large B-cell lymphoma in young adults: is this a distinct disease entity

Hong JY1¹, Yoon DH2, Suh C2, Huh J3, Do IG4, Sohn I4, Jo J4, Jung SH5, Hong ME6, Yoon H6, Ko YH6, Kim SJ7, Kim WS8.

Int J Hematol. 2015 Mar;101(3):273-8. doi: 10.1007/s12185-014-1728-2. Epub 2015 Jan 1.

Clinical features and treatment outcomes of primary cutaneous B-cell lymphoma: a single-center analysis in South Korea

Kim MJ1¹, Hong ME, Maeng CH, Jung HA, Hong JY, Choi MK, Kim SJ, Ko YH, Kim WS.

Cancer Sci. 2015 Feb;106(2):186-93. doi: 10.1111/cas.12588. Epub 2015 Feb 4.

Prognostic significance of metabolic tumor burden by positron emission tomography/computed tomography in patients with relapsed/refractory diffuse large B-cell lymphoma

Tateishi U1¹, Tatsumi M, Terauchi T, Ando K, Niitsu N, Kim WS, Suh C, Ogura M, Tobinai K.

Acta Haematol. 2015;133(2):179-82. doi: 10.1159/000362149. Epub 2014 Oct 11.

Pilot Trial of Systemic Methotrexate plus R-CHOP Regimen with Intrathecal Methotrexate for Simultaneous Central Nervous System and Systemic Diffuse Large B Cell Lymphoma

Yoo KH1¹, Lee JY, Lim SH, Ko YH, Kim SJ, Kim WS.

Ann Hematol. 2015 Jan;94(1):71-8. doi: 10.1007/s00277-014-2171-4. Epub 2014 Aug 2.

Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer/T-cell lymphoma patients

Kim SJ1¹, Park S, Kang ES, Choi JY, Lim do H, Ko YH, Kim WS.

Leuk Lymphoma. 2015 Jan;56(1):194-201. doi: 10.3109/10428194.2014.911860. Epub 2014 Jun 25.

PKD1 is critical for Epstein-Barr virus LMP1-induced protection of malignant B cells from cell death induced by rituximab

Kim JH1¹, Kim WS, Park C.

Leuk Lymphoma. 2014 Sep;55(9):2196-8. doi: 10.3109/10428194.2013.871279. Epub 2014 Feb 17.

Dexamethasone, methotrexate, ifosfamide, L-asparaginase and etoposide (SMILE) chemotherapy for relapsed or refractory adult lymphoblastic lymphoma

Chang WJ1¹, Ko YH, Kim SJ, Kim WS.

Anticancer Res. 2014 Aug;34(8):4299-306.

Renal Insufficiency in Newly-diagnosed Multiple Myeloma: Analysis According to International Myeloma Working Group Consensus Statement

Park S1¹, Han B2, Kim K3, Kim SJ1, Jang JH1, Kim WS1, Jung CW1.

Cancer Res Treat. 2014 Jul;46(3):307-11. doi: 10.4143/crt.2014.46.3.307. Epub 2014 Jul 15.

Unusual Manifestation of Intravascular Large B-Cell Lymphoma: Severe Hypercalcemia with Parathyroid Hormone-Related Protein

Ha JM1¹, Kim E, Lee WJ, Hwang JW, Yune S, Ko YH, Choi JY, Kim SJ, Kim WS.

Biomed Res Int. 2014;2014:437852. doi: 10.1155/2014/437852. Epub 2014 Jul 10.

Comparison of the Freiburg and Charlson Comorbidity Indices in Predicting Overall Survival in Elderly Patients with Newly Diagnosed Multiple Myeloma

Kim SM1¹, Kim MJ1, Jung HA1, Kim K1, Kim SJ1, Jang JH1, Kim WS1, Jung CW1.

Acta Haematol. 2014;131(4):193-9. doi: 10.1159/000354839. Epub 2013 Nov 26.

Positive Correlation between Baseline PET or PET/CT Findings and Clinical Parameters in Multiple Myeloma Patients

Park S1¹, Lee SJ, Chang WJ, Maeng CH, Hong JY, Choi MK, Kim YS, Jung CW, Jang JH, Kim SJ, Kim WS, Choi JY, Kim K.

Nat Genet. 2014 Apr;46(4):371-5. doi: 10.1038/ng.2916. Epub 2014 Mar 2.

A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma

Yoo HY1¹, Sung MK2, Lee SH3, Kim S4, Lee H4, Park S5, Kim SC5, Lee B5, Rho K6, Lee JE6, Cho KH7, Kim W4, Ju H8, Kim J4, Kim SJ9, Kim WS9, Lee S4, Ko YH10.

Acta Haematol. 2014;131(3):156-61. doi: 10.1159/000353787. Epub 2013 Oct 31.

Matched-Pair Analysis Comparing the Outcomes of T Cell/Histiocyte-Rich Large B Cell Lymphoma and Diffuse Large B Cell Lymphoma in Patients Treated with Rituximab-CHOP

Kim YS1¹, Ji JH, Ko YH, Kim SJ, Kim WS.

Hum Pathol. 2014 Mar;45(3):556-64. doi: 10.1016/j.humpath.2013.10.023. Epub 2013 Oct 31.

CD798 and MYD88 mutations in diffuse Large B-cell Lymphoma

Kim Y1¹, Ju H2, Kim DH3, Yoo HY4, Kim SJ5, Kim WS5, Ko YH6.

Nutr Cancer. 2014;66(2):225-33. doi: 10.1080/01635581.2014.867065. Epub 2014 Jan 9.

Effect of Nutritional Status on Survival Outcome of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP

Park S1¹, Han B, Cho JW, Woo SY, Kim S, Kim SJ, Kim WS.

Ann Hematol. 2014 Nov;93(11):1895-901. doi: 10.1007/s00277-014-2137-6. Epub 2014 Jun 20.

Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study

Kim SJ1¹, Yang DH, Kim JS, Kwak JY, Eom HS, Hong DS, Won JH, Lee JH, Yoon DH, Cho J, Nam TK, Lee SW, Ahn YC, Suh C, Kim WS.

Vox Sang. 2014 Nov;107(4):407-15. doi: 10.1111/vox.12183. Epub 2014 Jul 31.

Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience

Lee KH1¹, Jung SK, Kim SJ, Jang JH, Kim K, Kim WS, Jung CW, Kim DW, Kang ES.

Leuk Lymphoma. 2014 Oct;55(10):2395-7. doi: 10.3109/10428194.2014.880429. Epub 2014 Mar 7.

Spinal cord compression in multiple myeloma: a single center experience

Jung HA1¹, Cho SH, Kim SJ, Jang JH, Kim WS, Jung CW, Kim K.

Acta Haematol. 2014;131(1):18-27. doi: 10.1159/000351060. Epub 2013 Sep 10.

Clinical Features and Treatment Outcomes of Intravascular Large B-Cell Lymphoma: A Single-Center Experience in Korea

Hong JY1¹, Kim HJ, Ko YH, Choi JY, Jung CW, Kim SJ, Kim WS.

Ann Hematol. 2014 Jan;93(1):99-105. doi: 10.1007/s00277-013-1952-5. Epub 2013 Nov 16.

DCEP for relapsed or refractory multiple myeloma after therapy with novel agents

Park S1¹, Lee SJ, Jung CW, Jang JH, Kim SJ, Kim WS, Kim K.

Ann Hematol. 2014 Sep;93(9):1531-40. doi: 10.1007/s00277-014-2091-3. Epub 2014 Jun 20.

Health-related quality of life in Korean lymphoma survivors compared with the general population

Kim SH1¹, Kim IR, Kim SH, Lee S, Ok O, Kim WS, Suh C, Lee MH.

Onco Targets Ther. 2014 Sep 26;7:1717-22. doi: 10.2147/OTT.S67380. eCollection 2014.

Brentuximab vedotin for relapsed or refractory CD30+Hodgkin lymphoma: a multicenter analysis from Asia

Yang QM1¹, Hong JY2, Ko YH3, Lin SY4, Au WY4, Choi MK5, Park S6, Kim SJ6, Kim WS6.

Bone Marrow Transplant. 2014 Jul;49(7):902-6. doi: 10.1038/bmt.2014.65. Epub 2014 Apr 28.

Allogeneic haematopoietic SCT for natural killer/T-cell lymphoma: a multicentre analysis from the Asia Lymphoma Study Group

Tse E1¹, Chan TS1, Koh LP2, Chng WJ2, Kim WS3, Tang T4, Lim ST4, Lie AK1, Kwong YL1.

Br J Haematol. 2014 Jun;165(6):768-76. doi: 10.1111/bjh.12819. Epub 2014 Mar 12.

A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma

Ogura M1¹, Ando K, Suzuki T, Ishizawa K, Oh SY, Itoh K, Yamamoto K, Au WY, Tien HF, Matsuno Y, Terauchi T, Yamamoto K, Mori M, Tanaka Y, Shimamoto T, Tobinai K, Kim WS.

Ann Hematol. 2014 Mar;93(3):437-47. doi: 10.1007/s00277-013-1884-0. Epub 2013 Aug 24.

Gene expression profiles for the prediction of progression-free survival in diffuse large B cell lymphoma: results of a DASL assay

Kim SJ1¹, Sohn I, Do IG, Jung SH, Ko YH, Yoo HY, Paik S, Kim WS.

Ann Oncol. 2014 Jan;25(1):182-8. doi: 10.1093/annonc/mdt530.

The impact of activated p-AKT expression on clinical outcomes in diffuse large B-cell lymphoma: a clinicopathological study of 262 cases

Hong JY1¹, Hong ME, Choi MK, Kim YS, Chang W, Maeng CH, Park S, Lee SJ, Do IG, Jo JS, Jung SH, Kim SJ, Ko YH, Kim WS.

Invest New Drugs. 2013 Dec;31(6):1514-21. doi: 10.1007/s10637-013-0015-z. Epub 2013 Aug 24.

A phase I study of everolimus and CHOP in newly diagnosed peripheral T-cell lymphomas

Kim SJ1¹, Kang HJ, Kim JS, Eom HS, Huh J, Ko YH, Lee J, Yim DS, Lee SY, Park WS, Yang WI, Lee SS, Suh C, Kim WS.

Lancet Oncol. 2013 Nov;14(12):e548-61. doi: 10.1016/S1470-2045(13)70450-9.

Management of B-cell non-Hodgkin lymphoma in Asia: resource-stratified guidelines

Tan D1¹, Tan SY, Lim ST, Kim SJ, Kim WS, Advani R, Kwong YL.

J Hematol Oncol. 2013 Nov 16;6:86. doi: 10.1186/1756-8722-6-86.

Extranodal natural killer/T-cell lymphoma involving the gastrointestinal tract: analysis of clinical features and outcomes from the Asia Lymphoma study group

Kim SJ1¹, Jung HA, Chuang SS, Hong H, Guo CC, Cao J, Hong XN, Suzuki R, Kang HJ, Won JH, Chng WJ, Kwong YL, Suh C, Song YQ, Zhu J, Tay K, Lim ST, Suzumiya J, Lin TY, Kim WS; Asia Lymphoma Study Group.

Eur J Cancer. 2013 Nov;49(16):3486-96. doi: 10.1016/j.ejca.2013.07.006. Epub 2013 Aug 1.

Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group

Kim SJ1¹, Hsu C, Song YQ, Tay K, Hong XN, Cao J, Kim JS, Eom HS, Lee JH, Zhu J, Chang KM, Reksodiputro AH, Tan D, Goh YT, Lee J, Intragumtornchai T, Chng WJ, Cheng AL, Lim ST, Suh C, Kwong YL, Kim WS.

Leuk Lymphoma. 2013 Sep;54(9):2035-40. doi: 10.3109/10428194.2013.769218. Epub 2013 Feb 28.

Epstein-Barr virus latent membrane protein 1 increases genomic instability through Egr-1-mediated up-regulation of activation-induced cytidine deaminase in B-cell lymphoma

Kim JH1¹, Kim WS, Park C.

J Clin Oncol. 2013 Jun 10;31(17):2103-9. doi: 10.1200/JCO.2012.46.5203. Epub 2013 May 6.

Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Ohmachi K1¹, Niitsu N, Uchida T, Kim SJ, Ando K, Takahashi N, Takahashi N, Uike N, Eom HS, Chae YS, Terauchi T, Tateishi U, Tatsumi M, Kim WS, Tobinai K, Suh C, Ogura M.

Repeated radioimmunotherapy with I-131-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma

Invest New Drugs. 2013 Apr;31(2):469-72. doi: 10.1007/s10637-012-9889-4. Epub 2012 Oct 28.

Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphoma

Ahn HK1¹, Kim SJ, Hwang DW, Ko YH, Tang T, Lim ST, Kim WS.

Int J Hematol. 2012 Nov;96(5):631-7. doi: 10.1007/s12185-012-1200-0. Epub 2012 Oct 12.

Waldeyer's ring marginal zone B cell lymphoma: are the clinical and prognostic features nodal or extranodal A study by the Consortium for Improving Survival of Lymphoma (CISL)

Oh SY1¹, Kim WS, Kim JS, Kim SJ, Lee S, Lee DH, Lee SI, Kang HJ, Choi CW, Park J, Song MK, Kim HJ, Kwon JH, Kwak JY, Bae SH, Park BB, Do YR, Lee HS, Jeong SH, Suh C, Kim HJ.

Eur J Cancer. 2012 Nov;48(17):3223-31. doi: 10.1016/j.ejca.2012.06.003. Epub 2012 Jul 4.

Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: A multicentre, single-arm, phase 2 trial

Kim SJ1¹, Yoon DH, Kang HJ, Kim JS, Park SK, Kim HJ, Lee J, Ryoo BY, Ko YH, Huh J, Yang WI, Kim HK, Min SK, Lee SS, Do IG, Suh C, Kim WS; Consortium for Improving Survival of Lymphoma (CISL) investigators.

Ann Oncol. 2012 Oct;23(10):2703-7. Epub 2012 Apr 29.

Extranodal natural killer/T-cell lymphoma from skin or soft tissue: suggestion of treatment from multinational retrospective analysis

Ahn HK1¹, Suh C, Chuang SS, Suzumiya J, Ko YH, Kim SJ, Huh JR, Yoon DH, Oh SY, Kim JS, Lee SI, Park KW, Hsieh PP, Nakamura S, Yoshino T, Ito K, Nagatani T, Oshimi K, Suzuki R, Kim WS.

Blood. 2012 Oct 11;120(15):2973-80. doi: 10.1182/blood-2012-05-431460. Epub 2012 Aug 23.

SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group

Kwong YL1¹, Kim WS, Lim ST, Kim SJ, Tang T, Tse E, Leung AY, Chim CS.

Leuk Res. 2012 Sep;36(9):1172-8. doi: 10.1016/j.leukres.2012.05.004. Epub 2012 Jun 2.

Rad knockdown induces mitochondrial apoptosis in bortezomib resistant leukemia and lymphoma cells

Yeom SY1¹, Lee SJ, Kim WS, Park C.

Am J Hematol. 2012 Sep;87(9):937-40. doi: 10.1002/ajh.23267. Epub 2012 Jun 23.

The impact of baseline and interim PET/CT parameters on clinical outcome in patients with diffuse large B cell lymphoma

Park S1¹, Moon SH, Park LC, Hwang DW, Ji JH, Maeng CH, Cho SH, Ahn HK, Lee JY, Kim SJ, Choi JY, Kim WS.

Int J Clin Exp Pathol. 2012;5(5):436-41. Epub 2012 May 23.

Mutation analysis of NF-kappa B signal pathway-related genes in ocular MALT lymphoma

Liu F1¹, Karube K, Kato H, Arita K, Yoshida N, Yamamoto K, Tsuzuki S, Kim W, Ko YH, Seto M.

J Hematol Oncol. 2012 Aug 13;5:49.

Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)

Kim YR1¹, Kim JS, Min YH, Hyunyoon D, Shin HJ, Mun YC, Park Y, Do YR, Jeong SH, Park JS, Oh SY, Lee S, Park EK, Jang JS, Lee WS, Lee HW, Eom H, Ahn JS, Jeong JH, Baek SK, Kim SJ, Kim WS, Suh C.

Leuk Lymphoma. 2012 Aug;53(8):1515-24. doi: 10.3109/10428194.2012.659735. Epub 2012 Mar 1.

Non-bacterial infections in Asian patients treated with alemtuzumab: a retrospective study of the Asian Lymphoma Study Group

Kim SJ1¹, Moon JH, Kim H, Kim JS, Hwang YY, Intragumtornchai T, Issaragrisil S, Kwak JY, Lee JJ, Won JH, Reksodiputro AH, Lim ST, Cheng AL, Kim WS, Kwong YL.

Leuk Lymphoma. 2012 Aug;53(8):1586-91. doi: 10.3109/10428194.2012.659736. Epub 2012 Mar 1.

Epstein-Barr virus latent membrane protein-1 protects B-cell lymphoma from rituximab-induced apoptosis through miR-155-mediated Akt activation and up-regulation of Mcl-1

Kim JH1¹, Kim WS, Park C.

Int J Cancer. 2012 Jul 1;131(1):235-43. doi: 10.1002/ijc.26352. Epub 2011 Aug 30.

Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy

Yhim HY1¹, Kim JS, Kang HJ, Kim SJ, Kim WS, Choi CW, Eom HS, Kim JA, Lee JH, Won JH, Shim H, Huh J, Lee DH, Suh C, Kwak JY.

Am J Hematol. 2012 Jul;87(7):663-8. doi: 10.1002/ajh.23213. Epub 2012 May 28.

Type II enteropathy-associated T-cell lymphoma: A multicenter analysis from the Asia Lymphoma Study Group

Tse E1¹, Gill H, Loong F, Kim SJ, Ng SB, Tang T, Ko YH, Chng WJ, Lim ST, Kim WS, Kwong YL.

Cancer Sci. 2012 Jun;103(6):1079-83. doi: 10.1111/j.1349-7006.2012.02251.x. Epub 2012 Mar 23.

Aggressive natural killer cell leukemia: Therapeutic potential of l-asparaginase and allogeneic hematopoietic stem cell transplantation

Ishida F1¹, Ko YH, Kim WS, Suzumiya J, Isobe Y, Oshimi K, Nakamura S, Suzuki R.

Leuk Lymphoma. 2012 May;53(5):807-11. doi: 10.3109/10428194.2011.635857. Epub 2011 Dec 7.

Pilot trial of yttrium-90 ibritumomab tiuxetan consolidation following rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy in patients with limited-stage, bulky diffuse large B-cell lymphoma

Yang DH1¹, Kim WS, Kim SJ, Kim JS, Kwak JY, Chung JS, Oh SY, Suh C, Lee JJ.

Ann Hematol. 2012 Apr;91(4):543-51. doi: 10.1007/s00277-011-1337-6. Epub 2011 Sep 16.

Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study

Kang HJ1¹, Kim WS, Kim SJ, Lee JJ, Yang DH, Kim JS, Lee SR, Lee GW, Kim HJ, Kim HY, Oh SY, Kim HC, Eom HS, Chung J, Park J, Suh C, Ryoo BY.

EMBO Rep. 2012 Apr;13(4):339-46. doi: 10.1038/embor.2012.3.

DeSUMOylating isopeptidase: a second class of SUMO protease

Shin EJ1¹, Shin HM, Nam E, Kim WS, Kim JH, Oh BH, Yun Y.

To SMILE or Not: Supportive Care Matters Reply

Acta Haematol. 2012;127(3):129-34. doi: 10.1159/000333139. Epub 2012 Jan 12.

Endoscopic Findings in Mantle Cell Lymphoma with Gastrointestinal Tract Involvement

Kim JH1¹, Jung HW, Kang KJ, Min BH, Lee JH, Chang DK, Kim YH, Son HJ, Rhee PL, Kim JJ, Rhee JC, Kim SJ, Kim WS, Ko YH, Kim JY.

Ann Hematol. 2012 Feb;91(2):223-33. doi: 10.1007/s00277-011-1297-x. Epub 2011 Jul 26.

Clinical features and outcomes of Hodgkin's lymphoma in Korea: Consortium for Improving Survival of Lymphoma (CISL)

Won YW1¹, Kwon JH, Lee SI, Oh SY, Kim WS, Kim SJ, Won JH, Kim KH, Park SK, Kim JS, Suh C, Yoon DH, Park JS, Kim MK, Kim H, Kang HJ, Mun YC, Kwak JY, Kim HJ, Eom HS.

Invest New Drugs. 2012 Feb;30(1):368-75. doi: 10.1007/s10637-010-9523-2. Epub 2010 Aug 24.

Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity

Kim SJ1¹, Kim K, Park Y, Kim BS, Huh J, Ko YH, Park K, Suh C, Kim WS.

Acta Haematol. 2012;127(2):100-4. doi: 10.1159/000333113. Epub 2011 Dec 15.

Primary Thyroid Marginal Zone B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue Type: Clinical Manifestation and Outcome of a Rare Disease - Consortium for Improving Survival of Lymphoma Study

Oh SY1¹, Kim WS, Kim JS, Kim SJ, Lee S, Lee DH, Kang HJ, Song MK, Kim HJ, Kwon JH, Kwak JY, Park BB, Do YR, Jeong SH, Suh C.

Ann Hematol. 2011 Dec;90(12):1409-18. doi: 10.1007/s00277-011-1227-y. Epub 2011 Apr 6.

Allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma who experienced relapse or progression after autologous stem cell transplantation

Kim JW1¹, Kim BS, Bang SM, Kim I, Kim DH, Kim WS, Yang DH, Lee JJ, Lee JH, Kim JS, Sohn SK, Yhim HY, Kwak JY, Yoon SS, Lee JS, Park S, Kim BK; Korean Society of Blood and Marrow Transplantation.

Ann Hematol. 2011 Dec;90(12):1391-8. doi: 10.1007/s00277-011-1225-0. Epub 2011 Apr 9.

Primary CNS lymphoma other than DLBCL: a descriptive analysis of clinical features and treatment outcomes

Lim T1¹, Kim SJ, Kim K, Lee JI, Lim do H, Lee DJ, Baek KK, Lee HY, Han B, Uhm JE, Ko YH, Kim WS.

J Clin Oncol. 2011 Nov 20;29(33):4410-6. doi: 10.1200/JCO.2011.35.6287. Epub 2011 Oct 11.

Phase II Study of SMILE Chemotherapy for Newly Diagnosed Stage IV, Relapsed, or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type: The NK-Cell Tumor Study Group Study

Yamaguchi M1¹, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, Izutsu K, Ishida F, Isobe Y, Sueoka E, Suzumiya J, Kodama T, Kimura H, Hyo R, Nakamura S, Oshimi K, Suzuki R.

Yonsei Med J. 2011 Nov;52(6):1044-7. doi: 10.3349/ymj.2011.52.6.1044.

Frontal Sinus Lymphoma Presenting As Progressive Multiple Cranial Nerve Palsy

Kim K1¹, Kim MJ, Ahn S, Bae SY, Kim WS, Yoon JH.

J Hematol Oncol. 2011 Aug 15;4:34. doi: 10.1186/1756-8722-4-34.

Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy

Kim YR1¹, Kim JS, Kim SJ, Jung HA, Kim SJ, Kim WS, Lee HW, Eom HS, Jeong SH, Park JS, Cheong JW, Min YH.

Ann Oncol. 2011 Jul;22(7):1636-43. doi: 10.1093/annonc/mdq645. Epub 2011 Jan 10.

Elevated LDH and paranasal sinus involvement are risk factors for central nervous system involvement in patients with peripheral T-cell lymphoma

Yi JH1¹, Kim JH, Baek KK, Lim T, Lee DJ, Ahn YC, Kim K, Kim SJ, Ko YH, Kim WS.

BMC Cancer. 2011 Jul 29;11:321. doi: 10.1186/1471-2407-11-321.

Multicenter retrospective analysis of 581 patients with primary intestinal non-hodgkin lymphoma from the Consortium for Improving Survival of Lymphoma (CISL)

Kim SJ1¹, Choi CW, Mun YC, Oh SY, Kang HJ, Lee SI, Won JH, Kim MK, Kwon JH, Kim JS, Kwak JY, Kwon JM, Hwang IG, Kim HJ, Lee JH, Oh S, Park KW, Suh C, Kim WS.

Asia Pac J Clin Oncol. 2011 Jun;7(2):136-45. doi: 10.1111/j.1743-7563.2011.01393.x.

Radioimmunotherapy with I-131-rituximab for patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL)

Kang HJ1¹, Lee SS, Kim KM, Choi TH, Cheon GJ, Kim WS, Suh C, Yang SH, Lim SM.

Ann Hematol. 2011 May;90(5):539-46. doi: 10.1007/s00277-010-1104-0. Epub 2010 Oct 20.

Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma

Kim SJ1¹, Oh SY, Kim JS, Kim H, Lee GW, Won JH, Shin HJ, Yang DH, Choi CW, Park J, Kim WS, Suh C.

Blood. 2011 Mar 24;117(12):3402-8. doi: 10.1182/blood-2010-09-310342. Epub 2011 Jan 26.

Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project

Weisenburger DD1¹, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA, Rudiger T, Pileri S, Nakamura S, Nathwani B, Campo E, Berger F, Coiffier B, Kim WS, Holte H, Federico M, Au WY, Tobinai K, Armitage JO, Vose JM; International Peripheral T-cell Lymphoma Project.

Invest New Drugs. 2011 Feb;29(1):154-60. doi: 10.1007/s10637-009-9320-y. Epub 2009 Sep 16.

Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin's lymphoma: a consortium for improving survival of lymphoma (CISL) trial

Park BB1¹, Kim WS, Eom HS, Kim JS, Lee YY, Oh SJ, Lee DH, Suh C.

Blood. 2011 Feb 10;117(6):1958-65. doi: 10.1182/blood-2010-06-288480. Epub 2010 Dec 9.

Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy alone

Kim SJ1¹, Kang HJ, Kim JS, Oh SY, Choi CW, Lee SI, Won JH, Kim MK, Kwon JH, Mun YC, Kwak JY, Kwon JM, Hwang IG, Kim HJ, Park J, Oh S, Huh J, Ko YH, Suh C, Kim WS.

Int J Hematol. 2010 Dec;92(5):690-6. doi: 10.1007/s12185-010-0720-8. Epub 2010 Nov 18.

Treatment of localized extranodal NK/T cell lymphoma, nasal type

Kim SJ1¹, Kim WS.

Cell Signal. 2010 Dec;22(12):1858-63. doi: 10.1016/j.cellsig.2010.07.013. Epub 2010 Aug 4.

Epstein-Barr virus latent membrane protein 1 increases chemo-resistance of cancer cells via cytoplasmic sequestration of Pim-1

Kim JH1¹, Kim WS, Yun Y, Park C.

Cancer Sci. 2010 Nov;101(11):2443-7. doi: 10.1111/j.1349-7006.2010.01698.x.

Stage IV marginal zone B-cell lymphoma - prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study

Oh SY1¹, Kim WS, Kim JS, Kim SJ, Lee S, Lee DH, Won JH, Hwang IG, Kim MK, Lee SI, Chae YS, Yang DH, Kang HJ, Choi CW, Park J, Kim HJ, Kwon JH, Lee HS, Lee GW, Eom HS, Kwak JY, Suh C, Kim HJ.

Exp Ther Med. 2010 Nov;1(6):943-946. Epub 2010 Aug 26.

Schedule-dependent synergistic effect of rituximab on methotrexate chemotherapy against lymphoma of the central nervous system

Jin J1¹, Joo KM, Nam Y, Kim DH, Lee SJ, Jo MY, Jin Y, Kim HS, Seo SW, Kim SJ, Nam DH, Kim WS.

Int J Hematol. 2010 Oct;92(3):510-7. doi: 10.1007/s12185-010-0680-z. Epub 2010 Sep 14.

Multiple mucosa-associated lymphoid tissue organs involving marginal zone B cell lymphoma: organ-specific relationships and the prognostic factors. Consortium for improving survival of lymphoma study

Oh SY1¹, Kim WS, Kim JS, Kim SJ, Lee S, Lee DH, Won JH, Hwang IG, Kim MK, Lee SI, Chae YS, Yang DH, Kang HJ, Choi CW, Park J, Kim HJ, Kwon JH, Lee HS, Lee GW, Eom HS, Kwak JY, Lee WS, Suh C, Kim HJ.

Invest New Drugs. 2010 Aug;28(4):516-22. doi: 10.1007/s10637-009-9283-z. Epub 2009 Jun 23.

Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma

Kang BW1¹, Kim WS, Kim C, Jang G, Lee SS, Choi YH, Lee DH, Kim SW, Kim S, Ryu JS, Huh J, Lee JS, Suh C.

Ann Hematol. 2010 Jun;89(6):563-8. doi: 10.1007/s00277-009-0875-7. Epub 2009 Dec 19.

Pulmonary marginal zone B-cell lymphoma of MALT type-What is a prognostic factor and which is the optimal treatment, operation, or chemotherapy: Consortium for Improving Survival of Lymphoma (CISL) Study

Oh SY1¹, Kim WS, Kim JS, Kim SJ, Kwon HC, Lee DH, Won JH, Hwang IG, Kim MK, Lee SI, Chae YS, Yang DH, Lee GW, Choi CW, Park J, Suh C, Kim HJ.

Int J Hematol. 2010 Jun;91(5):886-91. doi: 10.1007/s12185-010-0580-2. Epub 2010 May 8.

A randomized trial of preemptive therapy for prevention of cytomegalovirus disease after allogeneic hematopoietic stem cell transplantation

Kim ST1¹, Lee MH, Kim SY, Kim SJ, Kim DH, Jang JH, Kim K, Kim WS, Jung CW.

BMC Cancer. 2010 Jun 22;10:321. doi: 10.1186/1471-2407-10-321.

Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study

Yhim HY1¹, Kang HJ, Choi YH, Kim SJ, Kim WS, Chae YS, Kim JS, Choi CW, Oh SY, Eom HS, Kim JA, Lee JH, Won JH, Shim H, Lee JJ, Sung HJ, Kim HJ, Lee DH, Suh C, Kwak JY.

J Clin Oncol. 2010 May 10;28(14):e229; author reply e230. doi: 10.1200/JCO.2009.27.7574. Epub 2010 Mar 29.

Concurrent Chemoradiotherapy for Limited-Stage Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type Reply

Shimada K¹, Suzuki R.

Am J Hematol. 2010 May;85(5):362-3. doi: 10.1002/ajh.21663.

Clinicopathological features and outcome of late relapses of natural killer cell lymphomas 10-29 years after initial remission

Au WY¹, Kim SJ, Yiu HH, Ngan RK, Loong F, Kim WS, Kwong YL.

Ann Oncol. 2010 May;21(5):1058-63. doi: 10.1093/annonc/mdp412. Epub 2009 Oct 22.

When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type

Kim SJ1¹, Oh SY, Hong JY, Chang MH, Lee DH, Huh J, Ko YH, Ahn YC, Kim HJ, Suh C, Kim K, Kim WS.

Invest New Drugs. 2010 Apr;28(2):171-7. doi: 10.1007/s10637-009-9260-6. Epub 2009 May 7.

Phase II study of Gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial

Oh SY1¹, Kim WS, Lee DH, Kim SJ, Kim SH, Ryoo BY, Kang HJ, Choi YJ, Chung JS, Kim HJ, Suh C.

Bone Marrow Transplant. 2010 Apr;45(4):801-2. doi: 10.1038/bmt.2009.240. Epub 2009 Sep 21.

Excessive toxicity of once daily i.v. BU, melphalan and thiotepa followed by auto SCT on patients with non-Hodgkin's lymphoma

Lee SC¹, Kim SJ, Lee DH, Kim WS, Suh C, Won JH.

J Clin Oncol. 2009 Dec 10;27(35):6027-32. doi: 10.1200/JCO.2009.23.8592. Epub 2009 Nov 2.

Phase II Trial of Concurrent Radiation and Weekly Cisplatin Followed by VIPD Chemotherapy in Newly Diagnosed, Stage IE to IIE, Nasal, Extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma Study

Kim SJ1¹, Kim K, Kim BS, Kim CY, Suh C, Huh J, Lee SW, Kim JS, Cho J, Lee GW, Kang KM, Eom HS, Pyo HR, Ahn YC, Ko YH, Kim WS.

Am J Hematol. 2009 Dec;84(12):826-9. doi: 10.1002/ajh.21557.

Relapsed or refractory nongastric marginal zone B-cell lymphoma: Multicenter retrospective analysis of 92 cases

Oh SY1¹, Kim WS, Kim SJ, Kim JS, Kim SH, Lee DH, Won JH, Hwang IG, Kim MK, Lee SI, Kim JG, Yang DH, Kang HJ, Choi CW, Park J, Choi YJ, Kim HJ, Kwon JH, Suh C, Kim HJ.

Lancet Oncol. 2009 Nov;10(11):1093-101. doi: 10.1016/S1470-2045(09)70265-7.

Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009

Kwong YL1¹, Anderson BO, Advani R, Kim WS, Levine AM, Lim ST; Asian Oncology Summit.

Eur J Haematol. 2009 Aug;83(2):108-18. doi: 10.1111/j.1600-0609.2009.01252.x. Epub 2009 Mar 5.

Depletion of l-ascorbic acid alternating with its supplementation in the treatment of patients with acute myeloid leukemia or myelodysplastic syndromes

Park CH1¹, Kimler BF, Yi SY, Park SH, Kim K, Jung CW, Kim SH, Lee ER, Rha M, Kim S, Park MH, Lee SJ, Park HK, Lee MH, Yoon SS, Min YH, Kim BS, Kim JA, Kim WS.

Leuk Lymphoma. 2009 Jul;50(7):1110-8. doi: 10.1080/10428190902964776.

A retrospective study to compare two methotrexate-based regimens for primary central nervous system lymphoma

Uhm JE1¹, Kim KH, Yi SY, Chang MH, Park KW, Kong DS, Lee JI, Nam do H, Park W, Lim do H, Kim SJ, Kim K, Ko YH, Kim WS.

Cancer Chemother Pharmacol. 2009 Jun;64(1):27-33. doi: 10.1007/s00280-008-0847-y. Epub 2008 Oct 7.

A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin's lymphoma

Sym SJ1¹, Lee DH, Kang HJ, Nam SH, Kim HY, Kim SJ, Eom HS, Kim WS, Suh C.

Blood. 2009 Apr 23;113(17):3931-7. doi: 10.1182/blood-2008-10-185256. Epub 2008 Nov 24.

Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project

Au WY1¹, Weisenburger DD, Intragumtornchai T, Nakamura S, Kim WS, Sng I, Vose J, Armitage JO, Liang R; International Peripheral T-Cell Lymphoma Project.

Ann Oncol. 2009 Feb;20(2):390-2. doi: 10.1093/annonc/mdn726.

Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study

Kim SJ¹, Kim K, Kim BS, Suh C, Huh J, Ko YH, Kim WS.

Ann Hematol. 2009 Feb;88(2):111-9. doi: 10.1007/s00277-008-0544-2. Epub 2008 Jul 22.

Clinical features and prognostic factors of patients with "peripheral T cell lymphoma, unspecified"

Lee Y1¹, Uhm JE, Lee HY, Park MJ, Kim H, Oh SJ, Jang JH, Kim K, Jung CW, Ahn YC, Park K, Ko YH, Kim WS.

Biol Blood Marrow Transplant. 2009 Jan;15(1):118-25. doi: 10.1016/j.bbmt.2008.11.010.

Prognostic Factors and Clinical Outcomes of High-Dose Chemotherapy followed by Autologous Stem Cell Transplantation in Patients with Peripheral T Cell Lymphoma, Unspecified: Complete Remission at Transplantation and the Prognostic Index of Peripheral T Cell Lymphoma Are the Major Factors Predictive of Outcome

Yang DH1¹, Kim WS, Kim SJ, Bae SH, Kim SH, Kim IH, Yoon SS, Mun YC, Shin HJ, Chae YS, Kwak JY, Kim H, Kim MK, Kim JS, Won JH, Lee JJ, Suh CW.

Leuk Lymphoma. 2009 May;50(5):757-63. doi: 10.1080/10428190902803669.

Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma

Kim HS1¹, Kim KH, Kim KH, Chang MH, Ji SH, Lim do H, Kim K, Kim SJ, Ko Y, Ki CS, Jo SJ, Lee JW, Kim WS.

Med Oncol. 2008;25(4):447-50. doi: 10.1007/s12032-008-9065-z. Epub 2008 Apr 23.

Quality of life one year after chemoradiotherapy for localized primary gastric diffuse large B-cell lymphoma

Kim WS1¹, Park YH, Lee SH, Ryoo BY, Yang SH, Lee SS, Kim MS, Kim K, Park KW, Im do H, Kang JH, Lee J, Ko YH, Ahn YC, Lim do H, Park K, Bang SM.

Ann Oncol. 2008 Dec;19(12):2079-83. doi: 10.1093/annonc/mdn431. Epub 2008 Aug 9.

Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma

Lee J1¹, Suh C, Kang HJ, Ryoo BY, Huh J, Ko YH, Eom HS, Kim K, Park K, Kim WS.

Biol Blood Marrow Transplant.?2008 Dec;14(12):1356-64. doi: 10.1016/j.bbmt.2008.09.014.

Autologous Hematopoietic Stem Cell Transplantation in Extranodal Natural Killer/T Cell Lymphoma: A Multinational, Multicenter, Matched Controlled Study

Lee J1¹,?Au WY,?Park MJ,?Suzumiya J,?Nakamura S,?Kameoka J,?Sakai C,?Oshimi K,?Kwong YL,?Liang R,?Yiu H,?Wong KH,?Cheng HC,?Ryoo BY,?Suh C,?Ko YH,Kim K,?Lee JW,?Kim WS,?Suzuki R.

Leuk Lymphoma. 2008 Jul;49(7):1392-8. doi: 10.1080/10428190802087454.

SNARK, a novel downstream molecule of EBV latent membrane protein 1, is associated with resistance to cancer cell death

Kim JH1¹, Kim WS, Park C.

Cancer Chemother Pharmacol. 2008 Jul;62(2):299-304. Epub 2007 Oct 9.

Irinotecan plus cisplatin and dexamethasone (ICD) combination chemotherapy for patients with diffuse large B-cell lymphoma previously treated with Rituximab plus CHOP

Kang HJ1¹, Kim WS, Suh C, Park YH, Kim BS, Yuh YJ, Ryoo BY.

Cancer Sci. 2008 May;99(5):1016-20. doi: 10.1111/j.1349-7006.2008.00768.x. Epub 2008 Feb 19.

Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia

Yamaguchi M1¹, Suzuki R, Kwong YL, Kim WS, Hasegawa Y, Izutsu K, Suzumiya J, Okamura T, Nakamura S, Kawa K, Oshimi K.

Genes Chromosomes Cancer. 2008 Jan;47(1):1-7.

TNFAIP3 is the target gene of chromosome band 6q23.3-q24.1 loss in ocular adnexal marginal zone B cell lymphoma

Honma K1¹, Tsuzuki S, Nakagawa M, Karnan S, Aizawa Y, Kim WS, Kim YD, Ko YH, Seto M.

Leuk Lymphoma. 2008 Jan;49(1):88-94. doi: 10.1080/10428190701732861.

Clinical characteristics and outcome for hepatitis C virus-positive diffuse large B-cell lymphoma

Park BB1¹, Kim JS, Lee YY, Kang HJ, Ryoo BY, Kang JH, Kim HY, Kim BS, Oh SY, Kwon HC, Won JH, Kim K, Park K, Suh C, Kim WS.

Cancer Lett. 2007 Dec 8;258(1):90-7.

Nongastric marginal zone B-cell lymphoma: A prognostic model from a retrospective multicenter study

Oh SY1¹, Kwon HC, Kim WS, Park YH, Kim K, Kim HJ, Kwon JM, Lee J, Ko YH, Ahn YC, Oh SJ, Lee SI, Bang SM, Kim JH, Park J, Ryoo BY, Lee SS, Kim HY, Park K, Kim HJ.

Bone Marrow Transplant. 2007 Nov;40(10):919-24. Epub 2007 Sep 10.

Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma

Kim JG1¹, Sohn SK, Chae YS, Yang DH, Lee JJ, Kim HJ, Shin HJ, Jung JS, Kim WS, Kim DH, Suh C, Kim SJ, Eom HS, Bae SH.

Eur J Haematol. 2007 Oct;79(4):287-91. Epub 2007 Aug 10.

Intestinal marginal zone B-cell lymphoma of MALT type: clinical manifestation and outcome of a rare disease

Oh SY1¹, Kwon HC, Kim WS, Hwang IG, Park YH, Kim K, Ko YH, Ryoo BY, Kang HJ, Nam E, Lee JH, Kim JH, Kim HJ.

Am J Hematol. 2007 Sep;82(9):840-5.

Consideration of aggressive therapeutic strategies for primary testicular lymphoma

Park BB1¹, Kim JG, Sohn SK, Kang HJ, Lee SS, Eom HS, Kwon HC, Oh SY, Kang JH, Oh SJ, Shin HJ, Suh C, Kim JH, Kim HY, Kim K, Ryoo BY, Kim WS.

Genes Chromosomes Cancer. 2007 Aug;46(8):776-83.

Genome-wide array-based comparative genomic hybridization of ocular marginal zone B cell lymphoma: Comparison with pulmonary and nodal marginal zone B cell lymphoma

Kim WS1¹, Honma K, Karnan S, Tagawa H, Kim YD, Oh YL, Seto M, Ko YH.

Blood. 2007 Aug 1;110(3):972-8. Epub 2007 Mar 30.

The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma

Park S1¹, Lee J, Ko YH, Han A, Jun HJ, Lee SC, Hwang IG, Park YH, Ahn JS, Jung CW, Kim K, Ahn YC, Kang WK, Park K, Kim WS.

Leuk Res. 2007 Aug;31(8):1039-43. Epub 2006 Oct 6.

What is stage II in high-grade primary gastric lymphoma How to define the range of "localized disease"

Park YH1¹, Kim WS, Bang SM, Lee SI, Uhm JE, Yang SH, Lee SS, Park K, Ko YH, Ryoo BY.

Ann Hematol. 2007 Jul;86(7):493-8. Epub 2007 Mar 9.

Lymphoma-associated hemophagocytic syndrome: clinical features and treatment outcome

Han AR1¹, Lee HR, Park BB, Hwang IG, Park S, Lee SC, Kim K, Lim HY, Ko YH, Kim SH, Kim WS.

Am J Hematol. 2007 Jun;82(6):446-52.

Nongastric marginal zone B-cell lymphoma: Analysis of 247 cases

Oh SY1¹, Ryoo BY, Kim WS, Park YH, Kim K, Kim HJ, Kwon JM, Lee J, Ko YH, Ahn YC, Oh SJ, Lee SI, Kim HJ, Kwon HC, Bang SM, Kim JH, Park J, Lee SS, Kim HY, Park K.

Clin Cancer Res.?2007 Jun 1;13(11):3250-4.

Effect of positive bone marrow EBV in situ hybridization in staging and survival of localized extranodal natural killer/T-cell lymphorna, nasal-type

Lee J1¹,?Suh C,?Huh J,?Jun HJ,?Kim K,?Jung C,?Park K,?Park YH,?Ko YH,?Kim WS.

Leuk Res.?2007 Mar;31(3):359-64. Epub 2006 Aug 23.

Prospective clinical study of surgical resection followed by CHOP in localized intestinal diffuse large B cell lymphoma

Lee J1¹,?Kim WS,?Kim K,?Ahn JS,?Jung CW,?Lim HY,?Kang WK,?Park K,?Ko YH,?Kim YH,?Park C,?Yoon SH,?Lee WY,?Chun HK.

FEBS Lett. 2007 Feb 20;581(4):623-8. Epub 2007 Jan 18.

Egr-1, a new downstream molecule of Epstein-Barr virus latent membrane protein 1

Kim JH1¹, Kim WS, Kang JH, Lim HY, Ko YH, Park C.

J Drug Target. 2007 May;15(4):279-84.

Bio-distribution and anti-tumor efficacy of PEG/PLA nano particles loaded doxorubicin

Yu JJ1¹, Lee HA, Kim JH, Kong WH, Kim Y, Cui ZY, Park KG, Kim WS, Lee HG, Seo SW.

Leuk Lymphoma. 2007 Apr;48(4):716-22.

Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma

Park BB1¹, Ryoo BY, Lee JH, Kwon HC, Yang SH, Kang HJ, Kim HJ, Oh SY, Ko YH, Huh JR, Lee SS, Nam EM, Park KW, Kim JH, Kang JH, Bang SM, Park S, Kim K, Park K, Suh C, Kim WS.

Ann Hematol. 2006 Nov;85(11):781-6. Epub 2006 Jul 18.

Nodal marginal zone B-cell lymphoma: analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma

Oh SY1¹, Ryoo BY, Kim WS, Kim K, Lee J, Kim HJ, Kwon JM, Lee HR, Ko YH, Oh SJ, Park KW, Kim HJ, Kwon HC, Nam E, Kim JH, Park YH, Lee SS, Kim HY, Park K.

Leuk Lymphoma. 2006 Oct;47(10):2128-31.

High incidence of mucosa-associated lymphoid tissue in primary thyroid lymphoma: A clinicopathologic study of 18 cases in the Korean population

Cho JH1¹, Park YH, Kim WS, Oh SY, Cho SI, Kang HJ, Na II, Ryoo BY, Yang SH, Kim K, Jung CW, Park K, Ko YH, Lee SS.

Leuk Res. 2006 Oct;30(10):1253-8. Epub 2006 Mar 9.

Primary gastric lymphoma of T-cell origin: Clinicopathologic features and treatment outcome

Park YH1¹, Kim WS, Bang SM, Lee SI, Kang HJ, Na II, Yang SH, Lee SS, Uhm JE, Kwon JM, Kim K, Jung CW, Park K, Ko YH, Ryoo BY.

Eur J Haematol. 2006 Oct;77(4):304-8. Epub 2006 Jul 27.

Prognostic factor analysis and proposed prognostic model for conventional treatment of high-grade primary gastric lymphoma

Park YH1¹, Kim WS, Bang SM, Lee SI, Uhm JE, Kang HJ, Na II, Yang SH, Lee SS, Kim K, Jung CW, Park K, Ko YH, Ryoo BY.

Ann Hematol. 2006 Jul;85(7):463-8. Epub 2006 Mar 14.

The effect of Epstein-Barr virus status on clinical outcome in Hodgkin's lymphoma

Kwon JM1¹, Park YH, Kang JH, Kim K, Ko YH, Ryoo BY, Lee SS, Lee SI, Koo HH, Kim WS.

Leuk Lymphoma. 2006 Jul;47(7):1253-9.

CHOP followed by involved field radiotherapy for localized primary gastric diffuse large B-cell lymphoma: Results of a multi center phase II study and quality of life evaluation

Park YH1¹, Lee SH, Kim WS, Bang SM, Ryoo BY, Yang SH, Lee SS, Kim MS, Kim K, Park KW, Im do H, Kang JH, Lee J, Ko YH, Ahn YC, Lim do H, Park K.

Ann Hematol. 2006 May;85(5):285-90. Epub 2006 Mar 4.

Gastric Burkitt lymphoma is a distinct subtype that has superior outcomes to other types of Burkitt lymphoma/leukemia

Park YH1¹, Kim WS, Kang HJ, Na II, Ryoo BY, Yang SH, Lee SS, Uhm JE, Kim K, Jung CW, Park K, Ko YH.

Bone Marrow Transplant. 2006 May;37(9):819-24.

High-dose chemotherapy with autologous stem cell transplantation in extranodal NK/T-cell lymphoma: a retrospective comparison with non-transplantation cases

Kim HJ1¹, Bang SM, Lee J, Kwon HC, Suh C, Kim HJ, Lee JH, Ryoo BY, Park YH, Kwon JM, Oh SY, Lee HR, Kim K, Jung CW, Park K, Kim WS.

Haematologica. 2006 Mar;91(3):427-8. Epub 2006 Feb 17.

The effect of pre-irradiation dose intense CHOP on anthracyline resistance in localized nasal NK/T-cell lymphoma

Lee SH¹, Ahn YC, Kim WS, Ko YH, Kim K, Park K.

J Clin Oncol.?2006 Feb 1;24(4):612-8. Epub 2005 Dec 27.

Extranodal natural killer T-cell lymphoma, nasal-type: A prognostic model from a retrospective multicenter study

Lee J1¹,?Suh C,?Park YH,?Ko YH,?Bang SM,?Lee JH,?Lee DH,?Huh J,?Oh SY,?Kwon HC,?Kim HJ,?Lee SI,?Kim JH,?Park J,?Oh SJ,?Kim K,?Jung C,?Park K,?Kim WS.

Cancer Chemother Pharmacol. 2006 Jan;57(1):91-6. Epub 2005 Nov 5.

Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer

Park SH1¹, Lee J, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Park YS, Kang WK, Park K, Kim S, Bang SM, Cho EK, Shin DB, Lee JH.

Leuk Lymphoma. 2005 Dec;46(12):1743-8.

IMVP-16/Pd followed by high-dose chemotherapy and autologous stem cell transplantation as a salvage therapy for refractory or relapsed peripheral T-cell lymphomas

Park BB1¹, Kim WS, Lee J, Park KW, Kang JH, Lee SH, Park JO, Kim K, Jung CW, Park YS, Im YH, Kang WK, Ko YH, Lee MH, Park K.

Eur J Cancer.?2005 Jul;41(10):1402-8.

Extranodal nasal type NK/T-cell lymphoma: Elucidating clinical prognostic factors for risk-based stratification of therapy

Lee J1¹,?Park YH,?Kim WS,?Lee SS,?Ryoo BY,?Yang SH,?Park KW,?Kang JH,?Park JO,?Lee SH,?Kim K,?Jung CW,?Park YS,?Im YH,?Kang WK,?Lee MH,?Ko YH,?Ahn YC,?Park K.

Br J Cancer.?2005 Apr 11;92(7):1226-30.

Nasal-type NK/T cell lymphoma: clinical features and treatment outcome

Lee J1¹,?Kim WS,?Park YH,?Park SH,?Park KW,?Kang JH,?Lee SS,?Lee SI,?Lee SH,?Kim K,?Jung CW,?Ahn YC,?Ko YH,?Park K.

J Cell Biochem. 2005 Mar 1;94(4):695-707.

Arsenic trioxide represses constitutive activation of NF-kappa B and COX-2 expression in human acute myeloid leukemia, HL-60

Han SS1¹, Kim K, Hahm ER, Park CH, Kimler BF, Lee SJ, Lee SH, Kim WS, Jung CW, Park K, Kim J, Yoon SS, Lee JH, Park S.

Biol Blood Marrow Transplant. 2005 Feb;11(2):122-8.

Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission

Lee SH1¹, Lee MH, Lee JH, Min YH, Lee KH, Cheong JW, Lee J, Park KW, Kang JH, Kim K, Kim WS, Jung CW, Choi SJ, Lee JH, Park K.

Cell Signal. 2005 Jan;17(1):111-9.

Activation of Rafl and the ERK pathway in response to L-ascorbic acid in acute myeloid leukemia cells

Park S1¹, Park CH, Hahm ER, Kim K, Kimler BF, Lee SJ, Park HK, Lee SH, Kim WS, Jung CW, Park K, Riordan HD, Lee JH.

J Cell Biochem. 2004 Oct 1;93(2):257-70.

L-ascorbic acid represses constitutive activation of NF-kappa B and COX-2 expression in human acute myeloid leukemia, HL-60

Han SS1¹, Kim K, Hahm ER, Lee SJ, Surh YJ, Park HK, Kim WS, Jung CW, Lee MH, Park K, Yang JH, Yoon SS, Riordan NH, Riordan HD, Kimler BF, Park CH, Lee JH, Park S.

Leuk?Lymphoma.?2004 Feb;45(2):339-44.

Intestinal lymphoma: Exploration of the prognostic factors and the optimal treatment

Lee J1¹,?Kim WS,?Kim K,?Ko YH,?Kim JJ,?Kim YH,?Chun HK,?Lee WY,?Park JO,?Jung CW,?Im YH,?Lee MH,?Kang WK,?Park K.

Int J Mol Med. 2003 Dec;12(6):827-30.

Promoter methylation and down-regulation of DAPK is associated with gastric atrophy

Kim WS1¹, Son HJ, Park JO, Song SY, Park C.

Br J Cancer. 2003 Nov 17;89(10):1865-9.

Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma

Guan Z1¹, Wang Y, Maoleekoonpairoj S, Chen Z, Kim WS, Ratanatharathorn V, Reece WH, Kim TW, Lehnert M.

Haematologica. 2002 Dec;87(12):1343-5.

Aggressive natural killer cell leukemia: clinical features and treatment outcome

Song SY¹, Kim WS, Ko YH, Kim K, Lee MH, Park K.

Eur J Cancer. 2002 Jan;38(1):75-81.

Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American lymphoma (REAL) classification

Kim K1¹, Kim WS, Jung CW, Im YH, Kang WK, Lee MH, Park CH, Ko YH, Ree HJ, Park K.

Ann Oncol. 2001 Mar;12(3):349-52.

CHOP followed by involved field radiation: Is it optimal for localized nasal natural killer/T-cell lymphoma

Kim WS1¹, Song SY, Ahn YC, Ko YH, Baek CH, Kim DY, Yoon SS, Lee HG, Kang WK, Lee HJ, Park CH, Park K.

Invest New Drugs. 2001;19(1):81-3.

Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma

Kim WS1¹, Kim MM, Choi HJ, Yoon SS, Lee MH, Park K, Park CH, Kang WK.

Anticancer Res. 2000 May-Jun;20(3A):1499-502.

Microsatellite instability(MSI) in non-small cell lung cancer(NSCLC) is highly associated with transforming growth factor-beta type II receptor(TGF-beta RII) frameshift mutation

Kim WS1¹, Park C, Hong SK, Park BK, Kim HS, Park K.

Anticancer Res. 1999 Jan-Feb;19(1A):301-6.

Reduced transforming growth factor-beta type II receptor (TGF-beta RII) expression in adenocarcinoma of the lung

Kim WS1¹, Park C, Jung YS, Kim HS, Han J, Park CH, Kim K, Kim J, Shim YM, Park K.